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ABSTRACT                                                                                                                                                                            
Carbon Nanotubes (CNTs) are highly attractive vehicles for the delivery of bio-
molecules into living systems specifically for applications in cancer therapy. Two main 
types of CNTs; single-walled (SWNT) and multi-walled (MWNT) have been 
investigated. Pristine CNTs are poorly soluble in aqueous solvents, and therefore need 
to be functionalized (f-CNT) to enhance their solubility and biocompatibility. The f-
CNTs possess the ability to cross cell membranes and enter cells consequently having 
the potential as vehicles for drug delivery. Polyethylene glycol (PEG400) and 
Pluronic®F127 (PF127) functionalized SWNTs and MWNTs have been investigated in 
this study for in vitro cancer therapy. Both have demonstrated high tumour suppression 
efficacy with respect to an anti-cancer drug Paclitaxel, when utilised solely. However, f-
CNTs for the delivery of anti-cancer agents for brain tumours, in particular the most 
common tumour Glioblastoma, have not been researched. The toxicity of these 
materials is another issue that requires further investigation. Cytotoxicity of CNTs is 
thought to be dependent on several characteristics such as length, purity and type of 
functionalization.                                                                                                                                           
The aim of this study was to characterize, functionalize and investigate in vitro cell 
cytotoxicity of f-CNTs with and without Paclitaxel (PTX).  As dispersing and 
stabilization agents two polymeric systems were used; PEG400 and PF127.  CNTs 
characteristics have been investigated by using various techniques and two stabilization 
and dispersing agents have been used for functionalization. 
Raman spectra have been recorded using two laser lines at 325 nm and 488 nm. 
Scanning Electron Microscopy (SEM) and Transmission Electron Microscopy (TEM) 
were used to analyse their structure and morphology. All samples were functionalized, 
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homogenised, centrifuged and their ζ-potentials were measured. CNTs were found to be 
in a size range of 100 nm to several microns long, with diameter values ranging from 07 
± 1.0 nm for SWNT and inner diameter I.D. 10-20 nm and 30-40 nm Outer Diameter 
values (O.D.) with 6-12 concentric walls for MWNT. Both SWNT and MWNT 
exhibited stability in both polymeric systems implemented even after a 10 day period. 
Particularly PEG400 based formulations showed superior performance in terms of 
greater ζ-potential values. Notable shifts in G-band were examined confirming the 
presence of f-CNTs. Higher entrapment efficiency was accomplished with f-CNTs 
reaching a maximum efficiency at 200 µg/ml.   
Cell lines SVGp12 and U87-MG were exploited for cytotoxicity evaluations. SWNT 
and MWNT demonstrated insignificant cytotoxic effects on SVGp12 (normal 
astrocytes) cell lines even at elevated concentrations of up to 15 mg/ml. Nevertheless, f-
CNTs showed significant reduction in the cell viability at low Paclitaxel concentrations 
on U87-MG grade IV Glioblastoma. As a selection of CNTs have been investigated by 
various researchers, it is exceptionally challenging to conclusively state whether or not 
they are indeed toxic.  
This research into CNTs has successfully examined the effects of co-formulation with 
various components and the potential effects on drug delivery for cancer cells. 
Conceptually, CNTs are rightfully labelled as the king of nanomaterials due to their 
elusive chemical and physical properties; ensure that they are likely to receive much 
attention in the not too distant future. 
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CHAPTER 1 
INTRODUCTION 
 
 
"He who asks is a fool for five minutes, but he who does not ask is a fool 
for ever." 
-Chinese proverb- 
 
1 
 
CHAPTER 1  
1.1 Introduction  
 
‘’Plenty room at the bottom’’ (Richard P. Feynman, 1959) 
 
Richard Feynman, infamously proposed a new field in 1959 in „which little has been 
done, but in which an enormous amount can be done, in principle‟. However, the actual 
term nanotechnology was never used. Subsequently in 1974 Taniguchi coined the term 
„Nanotechnology‟ to describe this field as having innumerate potential applications  
(Taniguchi 1974). However, the manipulation of matter on an atomic level was 
popularised by the work of Drexler during the 1980‟s (Drexler 1981). For mankind, 
nanotechnology has been documented as early as 500BC, surrounding claims of an 
ancient existence with the incorporation of 1.5% Carbon into Indian steel, exponentially 
increasing material strength. Records following, describe the use of this steel in the 
production of swords (Figure 1.1) in Damascus during the times of Alexander the Great  
(Srinivasan 2007).  
Whilst nanotechnology is an exceptionally vast field, it has a considerable number of 
sub-disciplines, notably; nanoengineering, nanophysics, and nanomedicine. A 
significant role is played in many applications such as catalysis and drug delivery 
systems exploiting the large surface area generated from the miniscule size of 
nanoparticles.  
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Figure 1.1 Damascus sword (Srinivasan, 2007) 
 
Carbon Nanotubes (CNTs) utilised in nanomedicine have attracted considerable interest 
since their first introduction by Iijima (Iijima 1991) using High Resolution 
Transmission Electron Microscopy (HR-TEM). The relationship between CNTs and 
fullerenes was discovered by Nobel Laureate winner, H. Kroto, (Kroto, Heath et al. 
1985). CNTs are conjoined and concentrically nested graphene cylinders of varied 
lengths possessing an ultra-high aspect ratio of greater than 10,000. Extensive research 
has been conducted into the synthesis, properties, functionalization and the immense 
range of potential applications of CNTs.  
 
The potential of CNTs in the delivery of bio-molecules for a range of applications has 
received significant interest as of late. Particularly transport of drugs into cancerous 
cells for the purpose of diagnostics and therapeutics. Pristine CNTs have inherent 
limitations, namely poor solubility, which inhibits their utilization in medical 
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applications. Pluralities of approaches to enhance their solubility have been 
investigated.  
 
Prior research has entailed polyethylene glycol (PEG) SWNTs (Zhuang et al. 2008) and 
Pluronic®F108 functionalized MWNTs (f-MWNT) (Kateb et al. 2007) investigated in 
vitro and in vivo applications. Both aforementioned studies demonstrated SWNT and 
MWNT achieving higher tumour suppression efficacy than an anti-cancer drug alone.   
Functionalized CNTs (f-CNTs) possess the ability to penetrate cells and have the 
potential for use as vehicles for drug delivery. However, f-CNTs for the delivery of 
anticancer agents in Glioma have yet to be explored offering scope for further research. 
Glioma is defined as a primary brain tumour arising from the Microglia (MG) and is 
considered as an immune effector in cells of the Central Nervous System (CNS) capable 
of phagocytosis. The process of phagocytosis entails the engulfment of particles to 
remove pathogens using specialised cells known as phagocytes. Precise selection of size 
and functionalization of CNTs may enable them to be eliminated by phagocytosis. The 
unique properties of CNTs reduce the limitations of anticancer drugs e.g. Paclitaxel 
(PTX), a drug which has known problems in bypassing the Blood Brain Barrier (BBB). 
Consequently, CNTs have a higher tumour reduction efficacy.   
 
Conversely toxicity of these materials is an issue which should receive due 
consideration. This may be evaluated through cytotoxicity assays. Cytotoxicity itself 
may be dependent on multiple characteristics, including the structure, length, purity and 
the type of functionalization.  One in vitro study utilising primary mouse microglia cells 
(MG-BV2) showed insignificant signs of cytotoxicity by evaluating the efficacy of 
MWNTs as potential nanoscale delivery vehicles (Bong J. et al 2011). 
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Studies using a multitude of CNTs purchased or synthesised from various sources are 
inconclusive with respect to toxicity (Lacerda L et al 2006). Therefore, preparation 
methods and conditions employed are influential on characteristics and purity. In this 
study, polyethylene glycol (PEG400) and Pluronic®F127 (PF127) have been affixed to 
SWNTs and MWNTs in order to increase their solubility.  
 
1.2 Aims and objectives   
The aim of this study was to characterize, functionalize and investigate in vitro cell 
cytotoxicity of f-CNTs. Two polymeric systems were utilized as dispersing and 
stabilization agents; PEG400 and PF127. An anti-cancer drug, PTX has been non-
covalently attached to f-CNTs. For cytotoxicity and cell entrapment investigation cell 
lines including U87-MG and normal astrocytes SVGp12 were utilised.   
Chemotherapy is an integral component in the treatment of most cancers. Sadly it is 
associated with low success rates due to the acquired resistance developed in cancer 
cells to chemotherapeutic agents. This study investigated the use of functionalized 
CNTs for drug delivery in anti-cancer applications, particularly in Glioma.  
Specific objectives identified were as follows: 
 Characterization of SWNTs, MWNTs and f-CNTs using an array of techniques 
including; ZetaSizer, Scanning Electron Microscopy (SEM), Transmission 
Electron Microscopy (TEM), X-ray Diffraction (XRD) and Raman spectroscopy 
for size, structure, surface area and charge analysis 
 Non-covalent functionalization of pristine SWNTs and MWNTs with PF127 
 Non-covalent functionalization of pristine SWNTs and MWNTs with PEG 
 Attachment of PTX onto SWNTs, MWNTs and f-CNTs 
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 Utilization of p-SWNTs, p-MWNTs and f-CNTs on cell lines, U87-MG and 
SVGp12 
 Cytotoxicity assay of p-SWNTs, p-MWNTs, f-CNTs and PTX-CNTs  
1.3 Outline of the thesis 
Chapter 1 provides an introduction summarising the aims and objective of the study, 
outlining the chapters contained in this thesis. 
Chapter 2 gives a detailed literature review of carbon materials and CNTs, their 
structure and properties and discusses their synthesis and applications.  
Chapter 3 entails a detailed experimental work pertaining to characterization and 
functionalization of SWNTs and MWNTs. Moreover, procedures used for studying 
their use in drug delivery systems and cytotoxicity are investigated.  
Chapter 4 contains results and discussions relating to the characterization and 
functionalization of SWNTs and MWNTs. 
Chapter 5 offers a description of the results and discussion from cytotoxicity studies 
for cell and tissue culture (in vitro) studies on Glioma and SVGp12 cell lines. 
Chapter 6 derives overall conclusions from the work conducted and proposed future 
work that may be carried out to deepen the comprehensions of this field. 
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CHAPTER 2 
CARBON BASED MATERIALS: 
APPLICATIONS &TOXICITY  
 
 
"Do not worry if others do not understand you. Instead worry if you do not 
understand others."  
(Confucius, 551-479 BC)
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 CHAPTER 2 
2.1 Carbon based materials 
Carbon is a remarkable element and materials based upon it have gained significant 
momentum in the field of nanotechnology in the previous quarter of a century. 
Scientists have developed several forms of carbon in addition to the two naturally 
existing allotropes; diamond and graphite.  Carbon is categorised as a Group 4 element 
consisting of 6 protons and neutrons in the nucleus, with electrons in the surrounding 
shells (Figure 2.1).        
 
Figure 2.1 Electronic structure and states of carbon 
A number of carbon isotopes exist which possess identical chemical properties due to 
their outer 4 electrons. 
 
In the ground state carbon has an electronic configuration of 1s
2
 2s
2 
2p
2
. In contrast in 
an excited state leading to bonding the one 2s and the two 2p orbitals hybridise forming 
sp orbital. This facilitates carbon in forming four covalent bonds with carbon or 
alternative elements. 
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2.2 Allotropes of carbon 
Diamond is considered one of the most attractive and useful allotropes (Figure 2.2) each 
atom tetrahedrally bonded to four other carbon atoms in a 3-dimensional network via 
covalent bonds. This gigantic structure imbibes diamond with a unique set of properties 
such as unparalleled hardness and an exceptionally high melting point (Asmann, 
Heberlein et al. 1999).  
 
 
Figure 2.2 Allotropes of carbon  
Graphite a second allotrope of carbon essentially comprises hexagonal layers which are 
structured through strong covalent bonding between carbon atoms in the arrangement of 
layers. The subsequent layers are held in place by weaker forces known as stacking 
interactions (van der Waals) however possess enough mobility to slide over one 
another.  
Planar graphene in graphite possess π electrons resulting in agglomeration, allowing van 
der Waals forces to develop within the layers. Fullerenes gather in a similar way and 
form fullerite crystals (Sengupta, Bhattacharya et al. 2011). 
9 
 
 
Recently graphene has attracted considerable interest as a wonder material. The 2010 
Nobel Prize was awarded to physicists Andre Geim and Konstantin Novoselov from the 
University of Manchester, UK “for ground breaking experiments regarding the 2-
dimensional material graphene”. Graphene offers interesting electrical, mechanical and 
optical properties. The application of graphene in the field of drug delivery is opening 
new avenues particularly in cancer treatment. In order to appreciate its grand potential 
the fundamental material characteristics require further understanding. Graphene is 
composed of a single layer of hexagonal carbon packed carbon structure with carbon 
atoms being sp
2 
hybridised. Strong covalent bonds within the planes contrast to weak 
attraction between the graphene sheets. The anti-cancer drugs can be entrapped or added 
to functionalized components and delivered to target cells (Yang 2011). Graphene 
additionally absorbs light strongly between the Ultra-Violet (UV) and Near Infra-Red 
(NIR) hence may be employed via photo thermal cancer therapy (Yang, Zhang et al. 
2010). Moreover, the fluorescent properties of graphene oxide can be utilised in optical 
based detection of biological molecules. As a single sheet graphene has a large surface 
area, a resultant large quantity of anticancer drugs may be loaded onto it.  
 
Studies have focused on the delivery of anticancer drugs to target tumour cells. The 
large surface area, thermal conductivity, the biocompatibility of graphene and the ability 
to functionalize this material makes it a promising candidate for the delivery of drug 
molecules, such as PTX, Doxrobucin (DOX) and Amphotericin B, as well as genes 
(Shen, Zhang et al. 2012). 
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 C60 commonly known as fullerene, an allotrope of carbon possesses an anatomical 
arrangement representing a „‟cage‟‟, which is hollow sphere, ellipsoid or a tube. The 
spherical form consists of 60 carbon atoms organized in a series of interlocking 
hexagons and pentagons. However, less spherical fullerenes are also formed such as 
C20, C36, C70 and C76 (Kroto, Heath et al. 1985).  
 
Another recently discovered structure of carbon is known as a Carbon Nanohorn (CNH) 
(Ge and Sattler 1994), which is composed of a single layered graphite sheet of 2-3 
nanometres (nm) in diameter. These sheets cluster into aggregates having a diameter of 
approximately 80 nm. Individual CNHs are cone shaped graphite structures with their 
tips capped with 5 member rings as may be observed in Figure 2.3. The diameter of 
CNHs increases as their length increases. Potential applications include artificial organs, 
molecular electronics, fuel cells and hydrogen storage.  
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                                                 (c)  
 
 
 
Figure 2.3 TEM micrographs of carbon nanohorns (a and b), with schematic diagram (c) 
for illustration (Bekyarova, Hanzawa et al. 2002)  
 
 
Alternative carbon based structures encompass nanobuds, nanocapsules, nanocoils and 
nanofibres (Figure 2.4). Having said this, detailed discussion of this structure exceeds 
the scope of this project.  
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Figure 2.4 (a) Nanocoils, (b) nanofibres, (c) nanocapsules and (d) nanobuds (Nasibulin, 
Pikhitsa et al. 2007) 
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2.3 CNTs and their properties 
CNTs are essentially „‟rolled‟‟ up layers of graphene sheets in a tubular structure. 
Though discovered 60 years ago by Radushkevich and Lukyanovich (Radushkevich and 
Lukyanovich 1952),  it only became apparent to the nanotechnology world through a 
rediscovery by the Japanese scientist Ijima (Iijima 1991). As previously mentioned 
there are various types of CNTs including: SWNTs, MWNTs and Double Walled CNTs 
(DWCTs) (Iijima and Ichihashi 1993). All exhibit unique physical and chemical 
properties which are highly dependent on the various fabrication methods discussed 
further on. The chemical bonding of CNTs are based upon the sp
2
 orbital bond, making 
them the strongest and hardest material documented in terms of tensile strength and 
elastic modulus respectively (Peng, Locascio et al. 2008). Depending on the chirality of 
the tubes the electrical properties can vary from being either metallic or 
semiconducting. The morphology of CNTs differ depending on the exact process 
conditions and preparation methods (Qian, Wagner et al. 2002).   
 
The reasons for functionalizing CNTs are multifarious including, improvement in their 
solubility, biodegradation and for the attachment of various molecules or drugs. They 
may be functionalized by the addition of a wide range of chemical groups to the ends 
and sidewalls. Additionally, chemical groups and drugs can be added to the inner of the 
tubes depending on the CNTs diameter and the size of the drug molecule (Bianco, 
Kostarelos et al. 2005).  
 
The high strength of the sp² carbon-carbon bonds imparts CNTs with greater 
mechanical properties, which can supply in vivo stability. Their high aspect ratio, 
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tendency towards functional modification and their ability to cross biological barriers 
are deemed as excellent nanocarriers for drug delivery (Kostarelos, Lacerda et al. 2007). 
Furthermore, they are advantageous in terms of being utilized as potential nanofluidic 
device for controlled drug delivery (Foldvari and Bagonluri 2008). 
2.3.1 Single walled CNTs 
A SWNT is composed of a rolled up single sheet of graphene in a cylindrical shape as 
illustrated in Figure 2.5  (Iijima and Ichihashi 1993). The cylindrical ends may be sealed 
by using two caps; each cap being composed of a hemi fullerene. All the carbon atoms 
are in equivalent positions in hexagonal aromatic rings, with the exception of atoms at 
the tips of the nanotubes. Pentagonal rings are also present at the tips of the tubes as 
these favour chemical reactivity (Baughman, 2002).  
 
The carbon atoms involved in the rings have alkene bonds (C=C) however are not 
planar due to hybridisation with some sp
3
 character which increases as the tubular 
diameter decreases. This effect is similar to that observed for C60 which has 
approximately 30% of sp
3
 bonding, with a radius of 0.35 nm. The surface of SWNTs is 
thus more reactive than the planar graphene. Variable overlapping of bonds of density 
states imparts onto SWNTs a unique and versatile electronic behaviour.  
 
A graphene sheet is composed of sp
2
 hybridised carbon atoms in a hexagonal shape. 
The joints between the caps and ends of the sheet are seamless. Whilst there is no 
restriction in the diameter, it appears that collapsing a single-walled tube into a flattened 
two-layered ribbon is energetically more favourable than the larger diameter tubular 
structure, particularly when the diameter supersedes ≈ 2.5 nm. Energetic and stresses 
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become unfavourable on lowering of the diameter beneath 0.4 nm. Figure 2.5(a) 
provides a description of a rolled up SWNT.  
Figure 2.5(b,c,d) shows the potential chiral configurations of assorted SWNTs i.e. 
Armchair, Zigzag and Chiral arrangements. A compromise may be reached with the 
most commonly occurring diameter ≈ 1.5 nm (which is in the mid-range). The lengths 
of CNTs however are variable ranging from nm to µm. The longest CNT length 
observed was reported to be 18.5 cm (Wang, Li et al. 2009). Features covering small 
diameters and long lengths give SWNT a very high aspect ratio. In contrast, short 
SWNTs are highly desirable for biomedical utilization, particularly for in vitro and in 
vivo, due to phagocytosis and cytotoxicity. There are three distinct ways into which a 
graphene sheet may be „‟rolled‟‟ into a tube. These structures give SWNTs well defined 
metallic, semi-conducting or semi-metallic properties, depending on the tube diameter 
and the chirality.  
 
Chirality of SWNTs is obtained from its chiral vector C which is defined by integers 
(n,m) obtained from the arrangement of hexagons with respect to the SWNTs axis. 
Arm-chair configuration is characterised by chiral vectors (n,n) with a perpendicular 
shape of the chair to the tube axis. Zigzag configuration is characterised by vectors (n,0) 
and has a V-shape perpendicular to the axis (Figure 2.5). All other vector configurations 
may be classified as chiral or helical. The chirality determines the electronic properties 
of the SWNTs allowing potential applications in a wide range of applications in the 
electronic industry.  
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Figure 2.5 Graphene sheet rolled up to obtain a SWNT adapted (a) from (Odom, Huang 
et al. 2000) and (b,c,d) from (Zhang, Wu et al. 2011) 
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2.3.2 Multi walled CNTs  
In many ways MWNTs (Iijima 1991) are inherently more complex than SWNTs. There 
are innumerate configurations from the basic graphene building block (Figure 2.6). The 
simplest arrangement involves a concentric arrangement in which successive tubes 
increase in diameter. Smaller tubes are contained within in turn into larger ones. 
MWNT have a number of walls, which may vary from two to an unlimited upper limit. 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.6 Typical MWNTs adapted from (Sanchez, Jachak et al. 2012) 
 
The diameter between tube walls within the MWNT is approximately 0.34 nm (Xie, 
Gan et al. 2008). The carbon atoms of graphene are positioned either opposite to one 
another or opposite carbon atoms from the neighbouring graphene. These enable the 
carbon nanotube to have a 3-D structure of graphite (Qian, Wagner et al. 2002). The 
MWNT do not possess as high or varied properties however are easier to process 
because of their larger diameter ranging from 10-50 nm with a length of 1-20 μm. As 
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grown by CVD their diameter may vary from 20-40 nm and 1-50 μm in length (Li, Wen 
et al. 2003). 
 
The herringbone is another common structure of MWNTs (Figure 2.7). Structurally, 
two graphene sheets are arranged at an angle with respect to the nanotube axis. The size 
of this angle is dependent upon the exact processing conditions employed for the 
synthesis, such as composition, catalyst used etc. The size of the angle varies from 0
o
 to 
90
 o
 considerably. The latter are often called nanofibres as opposed to nanotubes. The 
mechanism by which the herringbone structure is formed is yet to be concretely 
confirmed.  
 
 
 
Figure 2.7 Herringbone structure adapted from right (Strobel, Garche et al. 2006) and 
left from (Serp, Corrias et al. 2003)  
 
„‟Bamboo‟‟ textured graphenes, are also frequently encountered and may be viewed as a 
combination of the textures described above (Figure 2.8). It does not arise 
independently but contains a variable amount of herringbone and graphite textures. 
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These structures are hollow, but do not have an open inner cavity throughout the full 
length. They are often referred to as nanofibres rather than nanotubes. Nanofilaments 
are built from graphenes orientated perpendicular to the filaments axis and began as 
piled- up plates.  
 
 
Figure 2.8 Bamboo textured CNTs (Chizari, Janowska et al. 2010) 
 
MWNTs have an aspect ratio much lower than the SWNTs and the ends can often be 
viewed with a TEM and are shown to frequently contain a catalyst. The properties of 
MWNTs are highly dependent on the perfection and orientations of graphenes in the 
tubes, they are influenced by processing conditions and subsequent thermal or chemical 
treatments. The structures of CNTs may have an effect on their application in the area of 
drug delivery. They may also impact the functionalization and transport across 
membranes. However, no work to date has been carried out on the impact of the 
structure on drug delivery efficiency and mechanisms involved.  
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Carbon nanomaterials have had a profound and defying influence in all disciplines. In 
recent times each discovery has led to a greater one as may be seen in table 2.1. Dating 
early as 1952, when Radushkevich and Lukyanovich intruduced the Carbon filament.  
 
Table 2.1 Carbon nanomaterial discovery 
 
 
Year  Event  
1952 
Carbon filament (Radushkevich and 
Lukyanovich 1952) 
1960 
 Production of carbon tubes with graphite 
layer structure (Bacon 1960) 
1985 C60  (Kroto, Heath et al. 1985) 
1991 Multi-walled carbon (Iijima 1991) 
1993 
Single –walled CNTs (Iijima and 
Ichihashi 1993) 
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2.4 Synthesis of CNTs  
CNTs have been synthesised using a wide range of techniques including laser 
vaporisation, Arc-discharge, high-pressure carbon monoxide, CVD and plasma 
enhanced chemical vapour deposition (PECVD). Moreover, on the syntheses of CNT 
they require purification in order to be utilised for specific application. 
Functionalization of particular interest as the addition of chemical groups can facilitate 
transport and recognition of drug molecules.  
 
2.4.1 Solid sources 
This process requires high temperatures in excess of 800 
o
C and a solid source of carbon 
i.e. graphite is a pre-requisite. The types and properties of CNTs produced by solid 
methods are variable. Laser vaporisation of graphite was identified as the first to 
demonstrate the existence of a number of fullerenes many years ago with C60 being the 
most abundant and stable. The electric arc technique enables C60 to be produced in large 
quantities. However, in order to produce CNTs with these methods a catalyst is an 
essential requirement. In general, a catalyst speeds up the formation and growth of 
CNTs and metal catalysts are employed for CNT synthesis. In these methods energy is 
transferred from an external radiator (laser beam, solar energy or electric arc) to the 
target material. This causes the removal of material from the target source resulting in 
the formation of complex plasma containing a „‟soup‟‟ composed of free radicals, ion 
and neutral species. The extent of ionisation depends on various factors such as 
composition of the target, pressure, temperature and energy stored. The characteristics 
of the plasma such as density, composition and energy determine the characteristics of 
the CNTs synthesised. 
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The major advantage of these techniques is the possibility of varying a large number of 
parameters and enabling the formation of a range of CNTs. The optimum conditions can 
thus be defined for general CNT characteristics. Conversely, a pitfall would be that 
CNTs produced contain impurities such as other undesirable carbon phases and metal 
catalyst particles. Consequently, the of acids and thermal treatments are necessitated to 
obtain high quality purer CNTs (Djordjevic, Djustebek et al. 2006). 
 
2.4.2 Laser ablation 
In the laser ablation process a graphite pellet containing a catalyst is used. It is heated in 
a furnace containing an inert gas, such as argon, at a temperature of about 1200 
o
C 
(Figure 2.9). The Laser beam focused onto the target causes the material to vaporise. 
The carbon species is transported to another region in the reactor where it is deposited 
onto water cooled copper collector on the quartz reactor tube walls and the backside of 
the pellet. This method was the first used to synthesise fullerenes (Popov 2004).  
 
As of late modifications and considerable improvements to this method have been 
made. A second pulsed laser has also been employed which allows the carbon 
aggregates to follow the first ablation for CNTs growth. Researchers have also utilized 
second quartz tubes placed inside the larger tube coaxially to enable more carbon 
containing species to deposit. In addition, researchers have also employed two pellets, 
one made entirely of graphite and another made of a mixture of graphite and catalyst. 
Both of these are irradiated simultaneously.   
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Figure 2.9 Schematic diagram of a laser ablation system used for the growth of CNTs 
 
In this system a continuous CO2 laser beam (λ = 10.6 µm) is commonly utilized to 
ablate the graphite material. The laser power can be accurately controlled between 100 
W to 1600 W in order for the evaporation rate to be controlled. On increasing power, 
the evaporation rate also increases resulting in a higher growth rate of CNTs. 
Importantly control over the temperature in the reactor is a highly influential factor. An 
optical pyrometer is used to determine and control the temperature in the reactor. The 
solid products are transported away by the gas and collected at the filter. The yield is 
controlled by several factors such as the catalyst, cooling rate, residence time and the 
temperature.   
 
In the absence of a catalyst that is used in this method, the “soot” collected is composed 
mainly of MWNTs. Typically the lengths of the MWNTs are of the order ≈ 300 nm. 
CNTs obtained at 1200 
o
C deteriorate as temperature is reduced. In addition of catalysts, 
such as Ni or Co, the growth mechanism changes and SWNTs are formed. The type and 
the quantity of the catalyst used, determine the yield of SWNTs along with the furnace 
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temperature gradient. They have a uniform diameter and organise themselves into 
“rope-like” structures known to have varying lengths between 5-20 nm diameter and 10-
100 µm in length. The ends of the CNTs have closed caps on them. This technique has 
been used to prepare SWNTs commercially, with its ability to produce clean CNTs. As 
the technology advances this method may be replaced by alternative CNT methods with 
better control and output. 
 
2.4.3 Arc discharge  
In this technique the carbon is vaporised between two electrodes, the anode and 
cathode. Graphite is implemented in the form of rods, producing a cathode and the 
anode arranged horizontally and vertically (Figure 2.10). This is done in the presence of 
iron (Fe), nickel (Ni), cobalt (Co) and barium (B) etc. catalysts under reduced pressure 
in the presence of an inert gas such as argon.  Once the arc is triggered plasma is 
formed, consisting of a carbon vapour, gas and catalyst particles. Energy is transformed 
between the arc and the anode made out of graphite. The anode is eroded with the rate 
dependent on the power of the arc and the details of the experimental conditions. On 
completion CNTs are deposited in various regions of the reactor, including the cathode, 
reactor walls and bottom of the reactor.  
The electrode diameters are also variable. Two types of anodes are present, each 
contains holes which are drilled; allowing the graphite powder and catalyst to be 
introduced and mixed together in correct proportions. The graphite anode with the 
catalyst is homogenously dispersed.  
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Figure 2.10 Schematic diagram of an Arc discharge system 
 
Researchers have also investigated the use of electric arc within a liquid media such as 
water or liquid nitrogen. Greater ease in processing and the lack of requirement for a 
vacuum means this process can be set up to be continuous and therefore highly suitable 
for mass production.   
This method results in a variety of products such as CNTs, nanoparticles, fullerenes, 
nanofibres, MW Shells, single walled nanocapsules, and amorphous carbon. By altering 
the conditions such the anode, pressure etc. the type of product obtained varies. Anode 
is consumed and a “cigar like” deposit is formed. Outer parts of the deposit is MWNTs, 
polyhedral particles and amorphous carbon. SWNTs can be obtained by adding a 
catalyst such as Ni:Yttrium (Y), Fe:Co instead onto the anode. When a Fe catalyst is 
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used with H2 (Hydrogen) and inert gas, SWNTs are found with the length as high as 20-
30 cm and replacing He (Helium) with H2 gives MWNTs.  
 
2.4.4 Solar furnace  
The solar furnace technique also implements the principle of using sublimation of 
graphite powder and catalysts placed in a crucible (Figure 2.11). The solar energy is 
collected by a plane mirror and reflected towards a parabolic mirror which focuses onto 
the graphite pellet. Elevated temperatures results in vaporization of the pellet and 
catalyst simultaneously. The vapour then condenses onto a water cooled surface. The 
reactor consists of a support assembly cooled by water circulation, onto which a Pyrex® 
chamber is mounted. The target is mounted onto a Cu (Copper) rod which is surrounded 
by a graphite tube acting as a thermal screen and reduces losses of free radicals. The 
graphite crucible is filled with graphite powder for fullerenes and graphite plus catalyst 
for CNTs.  
 
On utilization of a Ni/Co catalyst at low pressure, MWNTs are the primary products. At 
high pressures smaller SWNTs are obtained. Ni/Y at high pressures, relatively long 
SWNT are obtained with diameters ranging from 1 to 2 nm.  
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Figure 2.11 Solar method for large scale CNT synthesis (adapted from Luxembourg, 
Flamant et al. 2004) 
 
2.4.5 Vapour phase deposition 
Catalytic decomposition of hydrocarbon has been known for over a century now. In the 
1980‟s Endo developed a floating catalyst reactor containing metallic catalyst particles 
with a diameter of 10 nm (Endo 1988; Belin and Epron 2005). CNTs are now widely 
produced using Catalytic Chemical Vapour Deposition (CCVD) technique (Kumar and 
Ando 2010). This method involves the decomposition of hydrocarbons in the presence 
of catalysts, which are normally transition metals such as Fe, Ni, Co etc. producing 
MWNTs and SWNTs. On usage of lower temperatures between 300-800 
o
C MWNTs 
are produced in an inert atmosphere of He or Ar (Argon). In contrast, at higher 
temperatures typically 600-1150 
o
C and in the presence of H2 and Ar SWNTs are 
produced. Plasma enhanced CVD (PECVD) using acetylene and H2 gas mixtures have 
been used to grow MWNTs onto steel plates. CVD has also been used to grow aligned 
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MWNTs and SWNTs substrates such as Ni, Si (Silicon), SiO2 (Silicon Dioxide), Cu/Ti 
(Titanium)/Si, stainless steel and glass (Bell, Teo et al. 2006).  
 
CNTs produced by this method differ from those produced by arc discharge particularly 
in that they have a lower degree of crystallinity and have more defects. CCVD is a 
versatile method for growing doped CNTs with B, N (Nitrogen) or both and can be 
centimeters in length with a diameter up to 10 nm. MWNT the number of walls can 
vary from 3 to more than 100. Diameters may potentially range up to 100 nm (Ionescu, 
Zhang et al. 2012). They tend to grow perpendicular to the substrate allowing ease in 
determination of their length using cross sectional SEM or TEM.  
 
The CVD process is simple in concept and consists of a furnace, which can be heated in 
a controlled manner to the required temperature. A mixture of hydrocarbon (CH4, C2H2, 
C2H4 or C6H6) an H2 or inert gas (He, Ar) is passed over small transition metal particles 
(Ni, Co, Fe) or a flat substrate with a thinly deposited layer of the transition metal onto 
the substrate (Si, Steel etc.) A catalytic chemical reaction occurs on the surface of the 
particle or flat substrate with the reaction rate being accelerated by the catalyst. 
Cracking of the hydrocarbon occurs onto the surface giving carbon. The below diagram 
offers a summary of the process:  
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 Cx Hx (g)     xC (s) + x/2 H2 (g) 
    
The carbon containing processor transfer other gases such as CO or CO2  
 
2 CO (g)     C (s) + CO2 (g)  
  
The growth characteristic of CNTs is dependent upon the process parameters entailing 
the pressure, catalyst, (type and size) of reactor, temperature, gas composition and flow 
rate.  The stages involved in the CCVD process are as follows:  
 Transport of gas mixture to the surface where the catalyst is present (particle or 
flat substrate) 
 Adsorption of the gases onto the surface 
Chemical reaction (decomposition) on the surface and subsequent growth of CNT ( 
 Figure 2.12Figure 2.12-Figure 2.13) 
 Desorption of unwanted byproducts such as H2 and unreacted species 
 Transport of products away from the surface and eventually out of the reactor 
 
A critical parameter in growing CNTs is the size and distribution of the catalytic 
nanoparticles. Control over the size is crucial and condensing in large clusters is highly 
undesirable. Condensation into large clusters is prevented by using support materials, 
such as Al2O3 (Aluminium Oxide), SiO2, MgAl2O4, MgO (Magnesium Oxide) and 
occasionally graphite. Generally, a low concentration of catalyst is required to limit the 
coalescence of the metal particles.  
      Catalyst  
 
        Heat  
      Catalyst  
 
        Heat  
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As the catalyst is a critical component in the CVD process it is informative to look at 
the myriad of ways in which this can be produced. Several methods are documented 
including impregnation which involves:  
 The salt solution (nitrate, chloride) containing the metal impregnates, the 
support material 
 Dry and calcinate the supported catalyst to obtain the oxide 
 Reduction in a H2 atmosphere to make metal nanoparticles 
 
Decomposition of carbon containing gas over freshly prepared metal particles to form 
CNTs. For example, C2H2 in H2 can be decomposed on a well dispersed metal particle 
such as Fe, Co, Ni, Cu that is supported on graphite or Co-SiO2 for MWNTs formation.  
 
The usage of zeolite support medium is implemented to support Co catalysis, with 
particle sizes of 1-50 nm in diameter only allow for the formation of two to three walls. 
CO (Carbon Monoxide) disproportionation has also been used to form CNTs onto nano-
sized Mo particles. The diameter is related to original particle size and ranges from 1 to 
50 nm.  
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Figure 2.12  Base growth model (Kumar, M. and Ando. A, 2010) 
 
 
Figure 2.13  Schematic view of widely accepted growth mechanism; tip-growth model 
(Kumar, M. and Ando. A, 2010)  
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The second involves solution-based methods where a solid solution of two metal oxides 
is formed on substitution of different metal ions. For example, a solid solution of Fe2O3 
(Ferrous Oxide) and Al2O3 are employed to form Al2-2xFe2xO complex solid solution. 
Both are homogenously inter-dispersed. Solid solutions of this type may be prepared in 
various ways for example, co-participation of mixed oxides. Homogeneous dispersions 
of catalytic oxide can produce very small catalytic metal oxides at high temperatures. 
18% CH4 in H2 decompose between 850-1050 
o
C. Nanotubes obtained are typically 
gathered into small diameter bundles less than 15 nm with lengths of 100 µm. The 
CNTs types are predominantly SWNTs and DWNTs with diameter ranging between 1-3 
nm. The defining issue is the ability to remove the catalyst and obtain pure CNTs.  
 
When oxides such as Al2O3 or SiO2 are used removal requires the usage of aggressive 
chemical treatments. Hot KOH (Potassium Hydroxide) or NaOH (Sodium Hydroxide) 
are used for Al2O3 and HF (HydroFuran) is used to remove SiO2. These solutions have 
no effect on other impurities such as other forms of carbon. Treatments such as 
oxidation in air, HNO3 (Nitric acid), KMNO4 (Potassium Permanganate) and H2O2 
(Hydrogen Peroxide) are required to remove carbon-containing impurities. However, 
the yield of CNTs attained is dependent on these oxidizing treatments.  
 
MgCoO (Magnesium Cobalt Oxide) solid solution has been previously used to prepare 
SWNTs and DWNTs. These may be easily be separated from the support by washing in 
aqueous HCl (Hydrochloric acid) solution without damaging the CNTs formed (Flahaut, 
Peigney et al. 2000). In addition, there is a homogeneous CCVD process, which has 
also been used to synthesize SWNTs and MWNTs. This method employs a hydrocarbon 
gas with H2/Ar mixture along with gaseous metal containing a precursor such as 
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ferrocene. The reactor contains two zones. The first zone is of a lower temperature and 
second zone is of a high temperature between 700-1200 
o
C. The metal precursor may be 
Fe(CO)5, ferrocene, nickelocene or cobaltocene (Awasthi, Kumar et al. 2011).  
In the first zone the metal organic compound decompose to generate metal particles, 
possessing a size in the nanometre range. The particles act as a catalyst for the CNTs 
synthesis. Both SWNTs and MWNTs may be formulated by this method. Difficulties 
experienced are again in the formation of several types of materials, control of particle 
size and removal of impurities. Often metal particles are too large to form CNTs but can 
still decompose the carbon containing precursor and form layers of graphene on the 
surface. Process parameters that affect the quality of CNTs are similar to the 
heterogeneous process such as the nature and size of the catalyst particles, reactor 
temperature, flow rate, residence time and composition of incoming gases and state of 
hydrogen.  
 
Notably the HiPCo (High Pressure Carbon Monoxixde) process developed at Rice 
University has been used to produce high quality SWNTs. This process implements CO 
and Fe(CO)5 (Iron Pentocarbonyl) in order to produce SWNTs relatively free of 
impurities. Hydrocarbon gases are required; however no alignment of CNTs can be 
recovered by dissolving the template (Bronikowski, Willis et al. 2001). 
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2.5 Biomedical applications of CNTs  
CNTs are novel carriers for small and large therapeutic molecules and may be 
functionalized using functional groups such as -NH3, -OH, -COH and -PEG in order to 
manipulate their physical or biological properties. These may be added to various 
locations in the CNTs such as within (encapsulation), tips and sides depending on the 
intended application (Figure 2.14) (Bhirde, Patel et al. 2009).  Furthermore, CNTs are 
able to act as carriers for therapeutic molecules, due to their large surface area and the 
manipulation of their surfaces and physical dimensions (Foldvari and Bagonluri 2008).  
There is a huge and increasing interest among biomedical scientists in the exploration of 
all of the above-mentioned properties which CNTs possess for Nano-biotechnology 
applications (Bianco, Kostarelos et al. 2005). CNTs are deemed a suitable substrate for 
the growth of cells for tissue regeneration, as delivery systems for a variety of 
diagnostic or therapeutic agents or as vectors for gene transfection (Becker, Fagan et al. 
2007). CNTs may be offered as a novel vector or transport system for various 
therapeutic agents to treat a variety of diseases.  
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Figure 2.14 Schematic representation of functionalization of SWNTs; adapted from 
(Bhirde, Patel et al. 2009) (a) with quantum dots, EDC and Cisplatin; (b) SWNT bio-
conjugated with Cisplatin and EGF, targeting cancer cell surface receptor EGFR; (c-e) 
TEM images showing the various functional groups, with Cisplatin shown as bright 
spots 
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2.6 Cancer  
Cancer is perhaps one of the most complex phenomena in biology and unfortunately 
each year more and more people are diagnosed with this often fatal disease. According 
to World Cancer Report 2008, there were 12.7 million new cases and an estimated 7.6 
million deaths from the disease (Error! Not a valid bookmark self-reference.) (Boyle 
and Levin 2008). 
 
Cancer can be broadly defined as a genetic disorder that is thought to be quite modern, 
although, the aphorisms of Hippocrates of Cos (born 460 BC) contains various 
references of malignant cancer, including “Every cancer not only corrupts the part it has 
seized but spreads further”. It is fundamentally a disease, whereby cell proliferation or 
apoptosis is disturbed (Figure 2.16). Typically, the human genome is very stable and 
many genetic alterations are required for cancer to occur. To elaborate, with the 
exception of reproductive cells, all cells divide by the process of mitosis which entails 
nuclear and cellular division. This process results in the production of two identical 
daughter cells. Any abnormality in one or both of the processes results in cell 
overgrowth which potentially may initiate cancer. Cell overgrowth can cause the 
formation of clusters remaining in a single mass in which the tumour is counted to be 
benign; this can more often not be completely cured. On the other hand a malignant 
tumour has the ability to invade the surrounding tissues; the end result may be 
secondary tumours or metastases. A cancerous tumour commonly originates from a 
single mutated abnormal cell (Alberts 1994). 
  
 
Figure 2.15 World cancer incidence in 2008 (adapted from (Boyle and Levin 2008) 
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Figure 2.16 Typical growth of normal cells and cancerous growth in uncontrolled 
manner adapted from (National Cancer Institute, NCI Website: (http: 
//cancer.gov/cancertopics/understandingcancer) 
 
Cancer cells have specific characteristic that are distinct form normal cells. A study by 
Hanahan and Weinberg established a model that is proposed as the “Hallmarks of 
Cancer”, after a decade of research they have broadened the scope of the concept, for a 
better understanding of cancer cells (Hanahan and Weinberg 2000). These six biological 
capabilities are acquired during tumour development to allow continuous and 
independent cell proliferation. These aforementioned hallmarks include; 
 Resisting apoptosis 
 Self-sufficient on growth factor 
 They can resist inhibitory signals from tumour suppressor genes 
 Stimulation of angiogenesis 
 Potential for limitless replication 
 Tissue invasion and metastasis 
The permutation of these characteristic make cancer a highly complex disease in terms 
of therapeutics. Apoptosis resistance is a crucial attribute of cancer cells along with 
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limitless replication, where they retain telomerase which sustains the telomere length of 
the chromosomes accomplishing a virtually immortal cell. A way in which cancer may 
metastasize is via the simulation of angiogenesis this plays an important role in rapid 
growth, since the new cells are in deprivation of nutrients and oxygen, at the same time 
they are able to override anti-growth signals (Hanahan and Weinberg 2011).   
 
Causes of cancer are dependent on internal and/or external factors. Internal factors may 
be attributed to genetic disorders, such as hormonal changes or immune system 
abnormalities. The environmental influences vary from; alcohol consumption, smoking 
tobacco to excessive sunlight exposure. Additional external factors may also include 
exposure to certain drugs, radiation and bacteria. Specific environmental factors may be 
linked to specific type of cancers; a key example would be the exposure of Benzidine 
resulting in a strong association with bladder cancer (You, Chen et al. 1990). Moreover, 
the smoking tobacco may cause various types of cancer such as; lung, bladder, lip, 
mouth and stomach cancer (Gandini, Botteri et al. 2008). In contrast, only one 
environmental factor is established for brain tumours, this is ionization radiation 
(Fisher, Schwartzbaum et al. 2007).  
 
Over 90% of Central Nervous System (CNS) tumours are initiated in the brain (Boyle 
and Levin 2008) and are classified as primary brain tumours. This may occur on brain 
cells, the membranes around the brain (meninges), nerves or glands. There are 
approximately 100 types of brain tumour. The most aggressive type is Glioma (Louis, 
Ohgaki et al. 2007). In the UK Brain tumours are listed as one of the most 20 common 
cancers, as it can be observed in Figure 2.17.  
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Figure 2.17 Twenty Most Commonly Diagnosed Cancers, adapted from Cancer 
Research UK statistics (2010) 
 
The tumour is named according to the type of cells and the area of the brain from which 
the abnormality stems. The most common brain tumour begins in glial cells and is 
referred to as Glioma. It is known for being an extremely aggressive tumour as 
described further on. 
 
According to the World health organisation (WHO) brain tumours can be classified and 
graded based upon their appearance under a microscope.  
 WHO grade I – Benign tissue which resembles normal brain cells, growth rates 
are often slow, removable and curable with surgery. 
 WHO grade II – Tissue is malignant and tends to spread, and looking less like 
normal cells. It often turns into high grade brain tumours with a poor prognosis. 
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 WHO grade III – In this grade the malignant tissue is anaplastic. (are actively 
growing)  
 WHO grade IV – This grade of tumours has poor prognoses and progress 
rapidly. This is the most aggressive malignant tumour. 
 
The possibility for low grade tumours to recur or to progress into higher grades (III and 
IV) is very common. However, the change is more common in adults than in children. 
The initial two types mentioned grow slower and can sometime be cured with treatment. 
The most common types of brain tumours are listed in table 2.2.  
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Table 2.2 Most common types of brain tumours  
Glioma Skull based tumours  Other types  
 Anaplastic Astrocytoma (grade III glioma) 
 Astrocytoma (grade II glioma) 
 Brainstem Glioma 
 Ependymoma 
 Gangliogliomas 
 Ganglioneuromas 
 Glioblastoma (Grade IV glioma) 
 Glioma 
 Juvenile Pilocytic Astrocytoma (JPA) 
 Low-grade Astrocytoma (LGA) 
 Medulloblastomas 
 Mixed Gliomas 
 Oligodendroglioma 
 Optic Nerve Gliomas 
 Pilocytic Astrocytoma (grade I glioma) 
 Primitive Neuroectodermal (PNET) 
 Acoustic Neuroma  
 (vestibular schwannoma) 
 Acromegaly 
 Adenoma 
 Chondrosarcomas 
 Chordomas 
 Craniopharyngiomas 
 Epidermoid Tumours 
 Glomus Jugulare Tumours 
 Infratentorial Meningiomas 
 Meningiomas 
 Pituitary Adenomas 
 Pituitary Tumour 
 Rathke's Cleft Cyst 
 Vestibular Schwannoma 
 Choroid Plexus Papillomas 
 CNS lymphoma 
 Colloid Cyst 
 Cystic Tumours 
 Dermoid Tumour 
 Germinoma 
 Lymphoma 
 Nasal Carcinomas 
 Naso-pharyngeal tumors 
 Pineal Tumours 
 Pineoblastoma 
 Pineocytoma 
 Supratentorial Meningiomas 
 Vascular Tumors 
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2.6.1 Glioma  
The most common type of primary brain tumour is Glioma and accounts for more than 
50% of cancer types and more than 90% of all primary malignant CNS tumours. They 
originate in the brain or the spine, as they arise from the glial cells (Figure 2.18). These  
protect and support the nerve cells (Kaye and Laws 2001). Gliomas exist in IV grades 
and nomenclature is based on the cells from which they grow including; hence gliomas 
that originate from astrocytes, ependymal and oligodendrocytes are referred to as 
astrocytoma, ependymoma and oligodendrocytoma, respectively. Some Gliomas 
contain more than one cell type and thus have the characteristics of both tumours, 
therefore treatment is harder to obtain and full recovery is significantly reduced. The 
grading is confirmed by preforming a pathological evaluation of the tumour. However, 
Gliomas are also classified according their histological cell features.  
 
Figure 2.18 Microglia cells showing the Glioma in the brain 
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Low grade (I and II) Gliomas are not anaplastic, meaning they remain in the cell 
structure and are less aggressive, although they grow, the growth factor is much less in 
comparison to the high grade (III and IV) whereby the growth is rapid and are 
anaplastic and thus the patients have poor prognosis.  
 
Histological nomenclatures of Gliomas:  
 Astrocytoma can be located anywhere in the brain and vary from grade I to IV. 
These neoplasms arise from astrocytes, the star-shaped brain cells, their 
characteristics vary from slow growth, invasion of surrounding tissue any cyst 
formation (Walker and Kaye 2001; Ohgaki and Kleihues 2005) 
 Ependyomomas are also glial tumour cells that usually occur in the lining of the 
ventricles (the brain passageways). Occasionally, this type of tumour does 
metastasise to the spinal cord but rarely originates from the cord itself. These 
neoplasms comprise approximately 5% of all CNS tumours and 15% of all 
spinal cord tumours. (Gilbert, Ruda et al. 2010; Nagasawa, Smith et al. 2011) 
 Oligodendroglioma is a tumour that is derived from the oligodendrocytes cells 
and was firstly recognized by Robertson in the 1900 as part of a neuroglial that 
was found mainly in the white matter of the CNS (Earnest, Kernohan et al. 
1950). Oligodendroglioma are classified into two forms: the well-differentiated 
oligodendroglioma and anaplastic oligodendroglioma. Additionally, 
oligodendrogliomas may occasionally contain clear evidence of neoplastic 
astrocytes and are considered as “mixed gliomas,” or most commonly as 
oligoastrocytomas. (Kleihues and Sobin 2000) 
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2.7 Cancer treatments 
Innumerate therapies have been uncovered since the 18
th
 century and already have been 
utilized for cancer treatment either solely or in combination with radiotherapy, 
chemotherapy, and/or surgery. Recently, however, a wide range of nanotechnology 
therapies have been shown to be effective in treatment of various cancers in vitro and in 
vivo (Misra, Acharya et al. 2010). This work focuses on chemotherapy and targeted 
delivery to cancerous regions specifically for primary central nervous system tumours. 
Brain tumours are considered to be the most difficult of cancers to treat, primarily due 
to the presence of the BBB and glioblastoma is the highest dedifferentiated form of 
astrocytic brain tumours, and it is refractory to chemotherapy in most cases.  
2.7.1 Radiation therapy  
Radiation therapy is used in conjunction to surgery and chemotherapy. The treatment 
consists of high energy beams that are produced by the accelerator to exterminate the 
cancer cells. However, the energy beams produced may kill surrounding healthy tissues, 
after extensive research in past decades doctors have determined the optimum doses for 
specific types of cancer that maximize effectiveness and minimize any harm to healthy 
tissues making radiotherapy a highly effective treatment. Various types of radiations 
exists, the most common type is however the external beam radiation therapy, whereby 
the high-energy beam is directed at the tumour (Hattangadi, Chen et al. 2010). 
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2.7.2 Surgery  
Nowadays, surgery is used within the context of multidisciplinary management of 
cancer, where it plays a role as one of the components of modern cancer management. 
Surgery can be used for multiple motives such as; cancer screening and prevention, 
surgery of cancer staging and surgery for cancer treatment. The choice for surgical 
intervention can be dependent on the nature and stage of the cancer type (Boyle and 
Levin 2008). 
2.7.3 Chemotherapy  
The mechanism of action in chemotherapy is based on the prevention of the rapid 
growth of mitosis or destroying the malignant cells, although their mechanism of action 
may vary with different drugs and concentrations levels. However, the major drawback 
of these drugs is that they damage and/or kill the healthy cells during the treatment 
(Karnofsky 1968). Several antineoplastic drugs are potentially available and that has 
been used to treat all cancer types (Table 2.3), among all only a number of them are 
more effective for treatment of brain tumour (Bredel 2001). 
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 Table 2.3 Anticancer drugs that have been used in the past decades 
Chloroethylnitrosoureas 
(CENUs) 
Antimetabolites Protein kinase C (PKC) 
inhibitors 
Carmustine (BNCU) Methotrexate (MTX) Tamoxifen 
Lomustine (CCNU) Edatrexate Bryostatin 
Nimustine (ACNU) 5-Fluorouracil (5-FU) 
7-Hydroxystaurosporine 
(UCN-01) 
Semustine (MeCCNU) Cytosine arabinoside (Ara-C) 
 Miscellaneous Agents: 
PCNU 6-Tioguanine (6-TG) 
HeCNU 5-Fluorocytosine (5-FC) 
Difluoromethylornithine 
(DFMO) 
NB-Fotemustine Bromodeoxyuridine (BrdU) Mechlorethamine 
Vinca alkaloids: Iododeoxyuridine (IUDR) Nitrogen mustard (HN2) 
Vincristine (VCR) Methylprednisolone (MPred) Mitoxantrone 
Vinblastine (VBL) Alkylating agents: Topotecan 
Epipodophyllotoxins: Temozolomide Etanidazole (ETA) 
Etoposide (VP-16) Procarbazine (PCB) Misonidazole (MISO) 
Teniposide (VM-26) Dacarbazine (DTIC) Irinotecan (CPT-11) 
Platinum compounds: 
Thiotepa Lovastatin 
Chlorambucil 
Methylglyoxal 
bisquanylhydrazide 
Cisplatin (CDDP) Busulfan Benznidazole 
Carboplatin Melphalan Didemnin B 
Phosphamides: 
Hydroxyurea (HU) Acivicin 
Gemcitabine Boswellic acids 
Cyclophosphamide (CPA) Spirohydantoin mustard (SHM) Thalidomide 
Ifosfamide Antibiotics: Eflornithine 
Mafosfamide Doxorubicin Piroxantrone 
 Taxanes: Idarubicin Hexitol derivatives: 
Epirubicin 
Paclitaxel Actinomycin D Dibromodulcitol (DBD) 
Docetaxel 
Bleomycin (Bleo) 
Dianhydrogalactitol (DAG) 
Aziridinylbenzoquinon (AZQ) 
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Drugs in bold are most commonly used for glioma. Temozolomide appears to be the 
current leading drug for high-grade gliomas. The efficacy of these anticancer drugs was 
determined to be only 20-25% in case of glioblastoma multiforme. Several factors apply 
for the poor prognosis, especially in the treatment of brain tumours. It originates at least 
in part from impermeability of the chemotherapeutic agents to BBB, inadequate drug 
exposure time, inadequate intracellular drug concentrations, and a number of other 
intracellular conditions (Bredel 2001). Paclitaxel is one of the chemotherapeutic agents 
that has been suggested as a therapeutic agent in treatment for Gliomas either alone or 
in combination with other approaches.  
 
Paclitaxel is a natural product extracted from Taxus yunnanensis and a microtubule 
inhibitor causing mitotic arrest; however it has poor solubility and therefore has 
restricted effectiveness in treatment. Various strategies have been proposed to find 
alternative to PTX to be non-toxic and still have high drug loading capacity. PEG has 
been used into the excipient to increase solubility, control drug release profile and 
increase blood circulation. However, PTX has been used widely as a hydrophobic drug 
to evaluate for sequestration in nanoparticles (Bredel 2001). Generally, PTX is a white 
to off-white crystalline powder and is highly lipophilic. Various forms of Paclitaxel are 
shown in Figure 2.19. 
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Figure 2.19 Various forms of PTX from natural and synthetic sources.                                                            
 
Paclitaxel treated cells have defects in mitotic spindle assembly, chromosome 
segregation, and cell division. It stabilizes the microtubule polymer and protects it from 
disassembly; its mechanism of action is shown in Figure 2.20.  
Since it is known that GBM cells are sensitive to Paclitaxel in vitro, (Glantz, Choy et al. 
1995) an enhanced delivery of Paclitaxel to the tumour cells in the CNS would be 
expected, to substantially help the chemotherapeutic prospect (Zhao, Liang et al. 2010). 
 
 
 
 
 
 
 
Figure 2.20 Paclitaxel mechanism of action  
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2.7.4 CNTs as carriers for cancer treatment  
Advanced nanotechnology has been widely utilized in the treatment of cancer (Portney 
and Ozkan 2006; Nagahara, Ferrari et al. 2009; Zhao, Liang et al. 2010). Due to their 
unique physiochemical properties, CNTs have been exploited as multipurpose 
innovative carriers for cancer therapy (Lacerda, Bianco et al. 2006; Xu, Meng et al. 
2010). The advantages of the utilization of CNTs in cancer therapy, specifically for 
brain tumours, is to improve the inadequate drug delivery, due to their properties that 
CNTs possess is to cross the BBB (Foldvari and Bagonluri 2008). Moreover, due to 
their distinct outer surface, wide range functional groups can be added to the tips and 
walls of CNTs making them amenable for functionalization with drug molecules (Chen, 
Chen et al. 2008; Chen and Schluesener 2010). A number of surfactants have been used 
to disperse and functionalize CNTs with PTX (Liu, Chen et al. 2008). The major 
advantage of non-covalent functionalization is that the electronic structure of the CNT‟s 
is preserved and the physical properties remain intact. CNT‟s have been used for cancer 
applications such lung, breast and brain tumours (Chen and Schluesener 2010). 
 
Previous research has shown that, CNTs are retained in the lymph nodes for a longer 
period when compared to spherical nanocarriers such as liposomes and can treat lymph 
node cancers (Reddy, Rehor et al. 2006). Magnetic nanoparticles may be entrapped into 
the MWNTs complex using anticancer drug Cisplatin. These nanoparticles are then 
utilised to move the nanotubes using a magnetic field to the lymph nodes in mice 
injected subcutaneously and released over several days to inhibit breast and lung cancer 
(Misra, Acharya et al. 2010).  
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In another study, anticancer effects have been demonstrated to be dependent on the 
method used to entrap the drug in the CNTs, which highlighted the possible effects of 
preparation conditions on the therapeutic activity of therapeutic molecules associated 
with CNTs (Hampel, Kunze et al. 2008). 
 
As can be seen in Figure 2.21 the structure morphology of CNTs may have various 
effects on cellular level whereby, the short CNTs can be engulfed and cleared out of the 
system through phagocytosis and long structures can have the adverse effect, of being 
toxic (Kostarelos 2008).  
 
 
Figure 2.21 Phagocytosis process of long and short CNTs. Adapted from (Kostarelos 
2008) 
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PEGylated nanotubes can prolong circulation and greatly enhance cellular uptake of the 
drug by the cancer cells (Liu, Chen et al. 2008). Anticancer activity was demonstrated 
by loading paclitaxel onto PEGylated SWNTs or MWNTs utilising HeLa cells and 
MCF-7 cancer cell lines (Lay, Liu et al. 2011). Using confocal microscopy hepatoma 
cell lines treated with PEGylated MWNTs accumulate in multidrug resistant cells with 
the same efficiency as in non-resistant cells (Cheng, Meziani et al. 2011). Liu et al 
interestingly reported that PEGylation of SWNTs prolongs blood circulation time of the 
associated anticancer molecule causing accumulation of the nanotubes in the dermal 
tissues of mice (Liu, Tao et al. 2011). Another remaining issue is that CNTs are cleared 
out of the body through the faeces (Liu, Cai et al. 2007).  
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2.8 Toxicity of CNTs  
Whilst, CNTs have enormous potential in drug delivery, there are still concerns 
surrounding  their toxicity, due to their small size and extremely high aspect ratio, they 
may still be a health hazard to living cells and the environment (Maurer-Jones, Bantz et 
al. 2009; Firme and Bandaru 2010). Generally, CNTs have been considered as being 
toxic due of their size although, the data are still fragmentary and subject to criticism. 
 
Dumortier and co-workers prepared two types of functionalized CNTs, following the 
1,3-dipolar cycloaddition reaction and the oxidation/amidation treatment, respectively 
and reported adverse effects that functionalized CNTs may have on cells of the immune 
system (Dumortier, Lacotte et al. 2006). Using in vitro studies, the uptake of 
functionalized CNTs were reported by B and T lymphocytes rapidly as well as 
macrophages without affecting the cell viability. Highly water soluble modified CNTs 
did not affect the functional activity of the immunoregulatory cells (Dumortier, Lacotte 
et al. 2006). Cui et al, examined the influence of single-walled CNTs (SWNTs) on 
human HEK293 kidney cells with the aim to explore SWNT biocompatibility (Cui, Tian 
et al. 2005) and found that SWNTs can inhibit cell proliferation and decrease the cell‟s 
ability to adhere in a dose and time-dependent manner. SWNT-treated HEK293 cells 
revealed acute and active responses to these nanotubes, such as the secretion of proteins, 
the aggregation of cells attached by SWNTs and the formation of subcellular nodular 
structures. Using cell cycle analysis they showed that 25 μg ml-1 SWNTs could arrest 
cell division at stage G and induce apoptosis. 
 
The potential pulmonary toxicity of SWNTs in revealed chronic inhalation and/or 
exposure to SWNTs could be a serious occupational health hazard (Lam, James et al. 
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2004). Histopathological studies on lungs treated for periods of 7 and 90 days after a 
single intratracheal instillation of SWNTs dispersion, showed that nanotubes induced 
epithelial granulomas and interstitial inflammation at day 7, which persist and 
developed to peribronchial inflammation and necrosis around day 90. Pharyngeal 
aspiration of SWNTs elicited unusual pulmonary effects in C57BL/6 mice, which 
resulted in acute inflammation accompanied with signs of the early onset of progressive 
fibrosis and granulomas (Shvedova, Kisin et al. 2005). 
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2.9 Conclusions 
This chapter highlighted several of advances that have been made in the utilization of 
CNTs, their properties and applications in cancer therapy. However, there are still 
tremendous opportunities and significant challenges to be unravelled. The challenges 
integrating CNTs with biomolecules are still being addressed.  
The small size and electronic properties of CNTs allow technologies to be developed 
that were otherwise not possible. Various of researchers have demonstrated that CNTs 
have the ability to enter cell membranes and were found to be non-toxic as these 
particles clear out from the body through faeces in the past years. The needle-like shape 
of the CNTs enables them to perforate cellular membranes and transport therapeutic 
molecules to the cellular components. This process is thought to take place via 
endocytosis. CNTs have exclusive properties that make them highly relevant in the 
medical field such as their ability to absorb pathogenic microorganisms and conduct 
heat. Furthermore, the results of the aforementioned studies are often inconclusive or 
contradictory. The data that has been presented in this review indicates that unrefined 
CNT possess some degree of toxicity mainly due to the transition metal catalysts 
presence. Exposures to pristine CNTs have been shown to elicit minimal cytotoxicity at 
higher concentrations (both in vivo and in vitro), whilst functionalized CNTs which 
enhance drug delivery without toxic effects.  
Hence, CNTs have been introduced to drug delivery research for a limited number of 
years and therefore extensive investigation and maximization is expected in the 
forthcoming years to explore their potential. Furthermore, no pre-clinical therapeutic 
effectiveness data is available yet for any specific disease with CNTs conjugated drug 
complexes. Radically different delivery system specifications are necessary for 
successful intercellular delivery and guaranteed biological activity of CNTs.
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CHAPTER 3  
MATERIALS, METHODS & 
TECHNIQUES 
 
“Curiosity is one of the permanent and certain characteristics of a 
vigorous mind.” 
(Samuel Johnson, 1709-1784)
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CHAPTER 3 
3.1 Materials and methods  
This chapter describes the materials and methods that have been used in this study.   
Initially, the purchased SWNTs and MWNTs were characterized using a range of 
techniques to demonstrate their size, morphology and structure. The materials were then 
functionalized to improve their solubility in aqueous solvents and increase their 
biocompatibility. Paclitaxel, a widely used anti-cancer drug, was attached to the 
functionalized CNTs. Glioma cell lines were employed for in vitro studies and 
subsequently, the CNTs complexes were investigated for cytotoxicity studies using 
MTT assay.  
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3.2 Materials  
Materials that have been used for this study are described in the following chapter.  
3.2.1 Carbon Nanotubes  
SWNTs and MWNTs with purity of more than 98% were purchased from Chengdu Ltd 
with SWNT diameter in the range of 1-5 nm and lengths between 100-500 nm. 
Purchased MWNTs exhibited outer diameters in the range of 10-20 nm and were 500-
1000 nm long. SWNTs and MWNTs were both produced by chemical vapour 
deposition (CVD). 
3.2.2 Surfactant and Paclitaxel 
Pluronic 127 (PF127), polyethylene glycol 400 (PEG400) and Paclitaxel (Taxol®) were 
purchased from Sigma Aldrich, UK and were prepared according to the material 
solubility.  Paclitaxel was stored at -20 ºC as received. The Paclitaxel stock solution was 
stored between 2-8 ºC as it is not stable and aqueous solution and samples were 
discarded after 1day.  
3.2.3 Cell and MTT assay 
SVGp12 normal astrocytes cells and U87-MG Grade IV glioblastoma cells were 
purchased from European Collection of Cell cultures (ECACC). The MTT assay kit 
suitable for in vitro cytotoxicity was purchased from Sigma, Aldrich, UK as well. 
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3.3 Characterization 
Characterization has been carried out for all utilized materials in this study, including 
SWNTs, MWNTs and f-CNTs. SEM and TEM were used to study the size and 
morphology. Raman spectroscopy was implemented to determine various characteristics 
of the CNTs. Zetasizer implemented to determine the zeta potential. TEM allowed the 
observation of the internal structure of samples, visualise the structure, demonstrate the 
number of walls and diameter size of the nanotubes.  
3.3.1 Scanning Electron Microscopy 
SEM is utilized to determine the morphology of fine structures of materials and 
nanoparticles, including CNTs ( Figure 3.1). Samples were obtained with Field 
Emission High Resolution Scanning Electron Microscopy, Hitachi S-4100 and Hitachi, 
SU 70. The resolution of secondary electron image of the microscope was 1.0 nm (at an 
accelerating voltage of 15 kV) or 2.5 nm at accelerating voltage of 1 kV. Accelerating 
voltage varied from 0.5 to 30 kV for low magnification from 25 to 19 000 times, and 
higher magnifications from 100 to 800 000 times in the high-resolution mode. The cold 
field emission Schottky Emitter gun was used as a source of electrons.  
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 Figure 3.1 Picture and schematic view of Scanning Electronic Microscopy 
 
3.3.2 Transmission Electronic Microscopy   
TEM forms major analysis method in a range of scientific fields (Jinschek and Helveg 
2012). In TEM, an electron beam from the electron gun passes through the 
electromagnetic condenser lens through the sample to an objective lens and then down 
to the phosphor screen or charge-coupled device (CCD) camera (Figure 3.2) 
In transmission electron microscope a beam of electrons is transmitted through an ultra-
thin sample. The condenser lens controls the size and intensity of the beam hitting the 
sample and the objective lens controls the magnification. TEM shows internal structures 
of specimen with magnification up to one million times revealing the structures in 
atomic resolution. Morphological and size examinations of freshly prepared blank, 
CNTs were done using negative staining solution. A droplet of the spontaneously 
formed CNTs samples, were placed onto a carbon-coated copper grid (400 mesh) for 
about 3 minutes in order to reach absorption equilibrium. The droplet was then wicked 
to dryness using pieces of filter paper before leaving the grid for another 1 minute. 
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Next, a droplet of the negative stain solution (2% Uranyl Acetate) was added to the 
surface of the grid. After 1 minute, the copper mesh grid was dried using pieces of filter 
paper and kept in a filter paper lined petri dish. The size, morphology and lamellarity of 
carbon nanotube samples were then viewed on Philips CM12 transmission electron 
microscope and photographed at an accelerating voltage of 8 kV. 
 
 
 
 
 
Figure 3.2 (a) Transmission Electronic Microscopy (b) TEM grid where the sample is to 
be viewed on (c) Schematic view of TEM adapted from (Marassi and Nobili 2009) 
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3.3.3 Raman Spectroscopy  
 
Raman spectroscopy principle is based on inelastic light scattering (Figure 3.3) 
complemented by the shift in photon frequency due to excitation or deactivation of 
molecular vibrations in which either the photon loses a proportion of energy or gains 
energy. The G-Line is a feature of the graphite layer which corresponds to the tangential 
vibration of the carbon atoms and second-order related harmonic G‟-band. The D-band 
sets the sign of the typical defects on the graphite structures. Comparison of the two 
peak intensities gives a measure of the quality of the CNTs. The third feature of Raman 
spectroscopy is the Radial Breathing Mode (RBM) which is sensitive to the diameter of 
SWNT (Figure 3.4). 
Raman spectra gives qualitative and quantitative information including; diameter, 
electronic structure (semi-conducting, metallic), purity, crystallinity and allows for the 
distinction between  metallic and semiconducting components. 
 
 
 
 
 
 
 
 
Figure 3.3 Schematic overview of Raman scattering
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Figure 3.4 Raman Spectra showing the characteristic features of CNTs (Belin and Epron 
2005) 
 
Two different wavelength laser excitations were used to characterize the materials and 
are mentioned in the forthcoming paragraph; 
UV set up; Raman spectra were obtained at room temperature in back scattering 
configuration with a Jobin-Yvon LabRam HR equipped with a Multichannel air cooled 
(-70 °C)  CCD detector. An objective of x40 magnification was used to focus the 
surface of sample pellet excited with the 325 nm HeCd laser line. 
Visible set up; Spectra were recorded on a triple subtractive Jobin Yvon T64000 
Raman spectrometer equipped with a liquid-nitrogen-cooled charge-coupled device 
(CCD) detector. The emission line at 488 nm from the Ar + ion laser was focused on the 
sample under the microscope. The time of acquisition was adjusted according to the 
intensity of the Raman scattering. The wavenumber values reported from the spectra are 
accurate to within 1 cm-1.  
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3.3.4 ζ-potential measurements  
Zeta potential (i.e, surface charge) of CNTs were analysed by injecting the sample into 
the plugs and voltage was applied through two gold plated electrodes ( 
Figure 3.5). The particle movement under the influence of an applied field was 
exploited to determine the zeta potential or effective charge of the particle on the basis 
of their electrophoretic mobility. This shows the amount of light scattered for the 
various contributions from the different charge. This process was established through 
the Zetasizer (Zetasizer nano zs, Malvern) that is equipped with the Zeta potential 
option.  
 
 
 
Figure 3.5 Schematic overview of zeta potential curette that has been used for 
measurements 
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3.4 Non-covalent functionalization  
Functionalization is a process where modification and coating of materials and 
functional groups can be added onto the CNTs surface. This process increases their 
solubility, dispersion in aqueous solutions and biocompatibility for biomedical 
applications. A vast range of functional groups may be added to the tips and walls of 
CNTs (Klumpp, Kostarelos et al. 2006).   
 
Two methods are commonly implemented to functionalize CNTs; these are covalent 
(Tagmatarchis and Prato 2004) and non-covalent bonding routes (Lay, Liu et al. 2011). 
Non-covalent functionalization holds the advantage that the structure of the CNTs is 
preserved with their physical properties remaining intact. Covalent functionalization 
also improves the solubility, however it has the disadvantage of altering the physical 
properties of CNTs. Hence non-covalent procedures were preferred for this study. There 
are a number of advantages and disadvantages to functionalization, these include the 
following:   
 The solubility in aqueous solvents is increased  
 The stability of the CNTs is improved considerably 
 Small drug molecules can be attached via chemical bonding onto the walls, the 
tips or they can be encapsulated 
 The cell toxicity is reduced significantly 
 
Two surfactants including PEG400 and PF127 were chosen for this study and are 
described in the following sections.  
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3.4.1 Functionalization of CNTs with Pluronic 
PF127 has been employed to functionalize the CNTs and are commonly used in 
biomedical applications due to their low toxicity and non-irritating behaviour. A 
multitude of methods have been employed to achieve these objectives (discussed in the 
previous chapters). For non-ionic polymers the dispersion is achieved due to 
hydrophilic counterparts. 
PF127 is a non-ionic triblock copolymer (Figure 3.6) with an additional property in 
aqueous solution: at or above room temperature, a solution of PF127 will convert from 
its liquid state to a non- fluid hydrogel. PF127 has already demonstrated significant 
ability to preserve polypeptide bioactivity in vitro and in vivo.  It is also deemed one of 
the most efficient and non-destructive surfactant amongst various compounds and 
highly biocompatible when used in low concentrations. With non-ionic surfactant CNT 
suspensions solubility appears to be due the size of the hydrophilic group. Higher 
molecular weights suspend a greater amount of nanotube due to the enhanced steric 
stabilization with longer chain polymeric groups being present (Klumpp, Kostarelos et 
al. 2006).   
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Figure 3.6 Chemical formula of Pluronic F127 with hydrophilic chains of 
polyoxyethylene,  hydrophobic chain of polyoxypropylene and Hydrophilic chains of 
polyoxyethylene 
  
I. PF127- suspension 
PF127 was dissolved in a weight ratio of 1% wt in  deionised water (DI) at room 
temperature.   
 
II. PF127 – CNT  
The appropriate amounts of 1:5 and 1:1 of SWNTs and MWNTs were added to the  
PF127 suspension whilst on bath sonication and left for 1 hour at high power. The 
suspension was then centrifuged to separate the f-CNT from the unreacted PF127-CNT 
at 122,000 g for 1 hour. The supernatant was used for characterization and sediment was 
re-suspend for Paclitaxel drug loading. 
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Table 3.1 Concentrations of CNTs in PF127 
 
3.4.2 Functionalization of CNTs with PEG400  
The process where CNTs are non-covalently functionalized with PEG is called 
PEGylation. This involves the use of PEG functional groups onto the CNTs to alter 
solubility (Figure 3.7). Polyethylene glycols are addition polymers of ethylene oxide 
and water, identified by a number which approximates their corresponding molecular 
weight. In order to prolong the circulation and minimize the opsonisation of CNTs, this 
is necessary for successful drug targeting. This can be achieved by coating of the CNTs 
with hydrophilic polymers/surfactants. Using a branched PEG for functionalization of 
CNTs enables more functional amine groups to be attached at the PEG terminal for 
more efficient drug conjugation. 
Functionalization of SWNT and MWNT-Concentration 1:1 with PF127 
SWNT 10 mg (SWNT-PF127) 9 ml  
MWNT 10 mg  (MWNT-PF127) 9 ml 
Functionalization of SWNT and MWNT-Concentration 1:5 with PF127 
SWNT  1 mg (SWNT-PF127) 4 ml 
MWNT 1 mg (MWNT-PF127) 4 ml 
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Figure 3.7 Non-covalent functionalization; surfactant chains onto the CNT 
 
I. Polyethylene glycol solution  
PEG400 was mixed with 1% w/w DI through gentle shaking. 
 
II. PEGylation 
Ratios were weighed and then transferred into 20 ml vial containing PEG400-DI. 
SWNTs and MWNTs were added to the solution and then ultrasonicated for 
approximately four hours until clear black suspension was obtained. For the f-CNT 
separation, the suspension obtained was centrifuged at 150 000 g for 1 hour and the 
supernatant was filtered with a molecular weight cut-off of 100 kDa (Millipore). This 
was followed by adding the suspension and then washed with DI six times to 
completely remove the unreacted PEG.   
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Table 3.2 Concentrations of CNTs in PEG400 
Functionalization of SWNT and MWNT- Concentration 1:1 with PEG400 
SWNT 10 mg (SWNT-PEG) 9 ml  
MWNT 10 mg (MWNT-PEG) 9 ml 
Functionalization of SWNT and MWNT- Concentration 1:5 with PEG400 
SWNT  1 mg (SWNT-PEG) 4 ml  
MWNT 1 mg (MWNT-PEG) 4 ml 
 
3.4.3 Paclitaxel   
Paclitaxel (PTX) stock solution was prepared, followed by mixing the appropriate 
concentration with the CNTs formulation (Table 3.3). 
 
I. Stock solution  
25 mg of Paclitaxel was weighed in a 100 ml volumetric flask which was then filled 
with absolute ethanol to make up the volume to 100 ml. The resultant solution was 
stirred until the paclitaxel was completely dissolved in the ethanol. A calibration curve 
of Paclitaxel was produced by making a serial dilution of 50-250 µg/ml using the 
equation: V1 C1 = V2 C2 from the stock solution and additional ethanol that was required. 
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II. PTX- f-CNT method 
 Each functionalized and pristine (p) (SWNT – MWNT) sample reacted with the 
required concentration of the modified PTX. PTX was weighted and modified 
according to concentration in glass vials and appropriate amounts of 10 ml for f-CNTs 
and 10mg of p-SWNT and p-MWNT were slowly added to each vial. After six hour 
reaction of ultrasonication, the resulting surfactant-CNT-PTX was purified to remove 
unconjugated PTX by filtration through 5 kDa MWCO filters and extensive washing.   
Table 3.3 Dilutions of stock solution for calibration curve 
 
Concentration  µg/ml Stock amount Dilution with ethanol 
50 20 µl 80 µl 
75 30 µl 70 µl 
100 40 µl 60 µl 
125 50 µl 50 µl 
150 60 µl 40 µl 
175 70 µl 30 µl 
200 80 µl 20 µl 
225 90 µl 10 µl 
250 1 ml 0  µl 
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3.5 Techniques  
The following techniques have been implemented for the purposes of functionalization, 
characterization and entrapment efficiency of PTX into CNT formulations.  
 
3.5.1 Probe-and Ultrasonication 
Sonication is one of the most commonly used methods, where a transducer is used to 
irradiate a liquid with a high pressure sound field with the resultant growth of cavities 
which implode violently with a localised release of energy. In a bath-type sonicator the 
sound field is almost uniform, with homogenous treatment of the suspension. Sonication 
has been used to disperse CNTs to in the aqueous solvents to improve efficiency and 
yield.  
3.5.2 Centrifugation technique  
Centrifuge technique is based upon the principle that particles of different density 
respond differently to gravity. With respect to this work low speed centrifugation has 
been used to separate amorphous carbon leaving behind the CNTs. CNTs sediment to 
the bottom of the centrifuge tube, whilst single nanotubes remain in the upper part. 
Sonication in aqueous solutions of surfactant followed by ultra-centrifuging is used to 
separate the individual CNTs. 
3.5.3 High performance liquid chromatography – loading efficacy of PTX  
Prior to the injection of the drug solution, the column was equilibrated for a minimum 
of 30 minutes with the mobile phase flowing through the system. High performance 
liquid chromatography (HPLC) is a chromatographic separation technique. In this 
study, the separation was achieved by HC-C18 column (250 × 4.6 mm, 4 µm, C18, 
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Agilent Technologies) at 35 °C. The CNT-PTX was dissolved in methanol, HPLC grade 
and sonicated for 10 minutes, thereafter centrifuged at 1000 g for 5 minutes. Once 
centrifuged, the supernatant was used for HPLC analysis (HPLC1200 instrument, 
Agilent, UK). 
 
Mobile phase: A = Water, B = acetonitrile; Injection volume: 5 μL; Temp: 25 °C; Flow 
rate: 1.0 ml/minutes; Gradient: at 0 minutes 50% B, at 10 minutes 90% B, Column 
wash: at 12 minutes 50% B; Stop time: 12 minutes; Post time: 5 minutes (Table 3.4). 
 
Table 3.4 HPLC gradient phase used for Paclitaxel 
Time in minutes A% (HPLC water)  B% (Acetonitrile) 
0 50 50 
10 10 90 
10.01 50 50 
17 50 50 
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3.6 Cell culture: Materials and Methods 
Cell culture procedures were conducted under aseptic conditions. Also all materials 
were sterilised via autoclaving prior to use. Step and procedures were carried out under 
a laminar flow hood. 
3.6.1 Glioma cell lines tissue culture to study glioma growth 
The growth of tissue or a cell on a surface e.g. glass or plastic, separated from the 
organism or in vitro growth in nutrient medium is commonly refers to the culture of 
animal cells and tissues. This is ordinarily facilitated via use of growth media or 
semisolid growth media such as broth or agar. Typically, there are two types of cell 
culture which employ similar practical sterile techniques (Mather and Roberts 1998). 
a. Primary cell culture - Culture consists of mixed population of cell types and the 
growth derived from the living organisms. Commonly, some of the cells may 
survive without proliferation and will therefore be lost in the increasing population 
of those which are able to multiply in in vitro.  
b. Established cell line - These cells are derived from a primary culture which can be 
sub-cultured in the medium indefinitely. 
3.6.2 Media importance in tissue culture 
Medium is essential to support the growth of the cells in tissue culture. A sample of 
tissue is either spread onto or added to a culture biological medium (e.g. blood serum) 
of either synthetic or mixed origin, having the appropriate nutrients, temperature and pH 
for the cells incubation. The media used for Glioma cell culture is Dulbecco‟s Modified 
Eagle Medium (DMEM) and Eagle‟s Minimal Essential Medium (EMEM). Cultured 
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materials must be incubated as close to the normal tissue environment. Sterile 
conditions are a requirement to maintain and to prevent contamination.  
3.6.3 Eagle’s Minimal Essential Medium and Dulbecco’s Modified Eagle Medium 
used for the proliferation of cells 
Development of Eagle‟s Minimum Essential Medium (EMEM), by Harry Eagle is one 
of the most widely used of all synthetic cell culture media for the cultivation of 
mammalian cells (Eagle 1955). EMEM has been broadly used for growing a wide 
variety of cells in mono-layers. It has to be stored at 15-30 °C. EMEM formulation may 
contain Earle's salts and a group of amino acids that are generally referred to as essential 
amino acids and non-essential amino acid (Table 3.5). There are twelve amino acids that 
are essential and can be used for the development of medium. The non-essential amino 
acids are optional and can be added to supplement the growth of cells. 
In their absence, irregularity in cell growth due to malnourishment of cells would cause 
an incorrect growth. 
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Table 3.5 List of essential and non-essential amino acids in EMEM. 
Essential Amino acids  Non- Essential amino acids  
L-arginine Alanine 
L-cystine Apartic Acid 
L-glutamine Asparagine 
L-histidine Cysteine 
,L-isoleucine Cystine 
L-leucine Glutamine 
L-methionine Glutathione 
L-phenylalanine Glycine 
L-threonine Proline 
L-tryptophan Serine 
L-tyrosine Threonine 
L-valine Taurine 
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EMEM contains higher concentrations of amino acids so the medium is more similar to 
the protein composition of mammalian cells. EMEM also requires FBS supplementation 
for providing growth promoting factor. Moreover, EMEM requires Sodium Pyruvate as 
a supplement for the growth of cells as Pyruvate is an intermediary organic acid 
metabolite in glycolysis and the first of the Embden Myerhoff pathway that can pass 
readily into or out of the cell. Thus, its addition to tissue culture medium provides both 
an energy source and a carbon skeleton for anabolic processes. Its addition may also 
help in maintaining certain specialized cells in cloning and may be necessary when the 
serum concentration is reduced in the medium (Culture of Animal Cells). 
 
A variation of this EMEM is called Dulbecco‟s Modified Eagle Medium (DMEM) 
(Dulbecco and Freeman 1959), this contains up to four times more vitamins, glucose 
and amino acids which are present in the original formula but it does not contain any 
proteins or growth promoting agents. Therefore, it requires supplementation to be a 
complete medium. Fetal bovine serum (FBS) is the most widely used growth 
supplement for cell culture media due of its high content of embryonic growth 
promoting factors and is usually supplemented to the media in concentration ranging 
from 5-10%. DMEM requires artificial levels of CO2 to maintain the required pH and 
therefore carbon dioxide (CO2) levels around 5-10% may be optimal for cell culture.  
Additionally, it contains iron and phenol red. DMEM is suitable for most types of cells, 
including human, monkey, hamster, rat, mouse, fish and chicken cell lines (Ham and 
McKeehan 1979). 
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3.7 Equipment and materials used for cell culture  
The materials and equipment that has been used for cell culture are shown in Table 3.6. 
Table 3.6 Materials and equipment used for cell culture 
Materials 
Cryovials, “Mr. Frosty” freezing container and liquid nitrogen 
DMSO (Sigma Aldrich, UK) 
Glioma cell lines (U87-MG, SVGp12) (ECACC, UK)   
Equipment 
New Brunswick Scientific (CO281R)- water jacketed CO2 incubator, 
Water bath 
Laminar flow hood 
Inverted phase contrast microscopes 
Weighing balance 
Tecan plate reader (Manufacturer: Tecan Austria GmbH, 2004 model) 
Refrigerator, freezer (- 20 °C) and deep freezer (-80 °C) 
Centrifuge machine 
Electrical aspirator 
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Equipment 
(continued from previous page) 
Vortex mixture 
2, 20, 200 and 1000 μl pipettes and pipette tips and motorized pipette controller 
75 cm
2
/25 cm
2 
culture flasks and 5 ml volumetric flask 
Sterile forceps  
5 and 10 ml disposable plastic pipettes and  15 ml and 50 ml centrifuge tubes 
0.22 μm and 0.44 μm sterile filters (Fisher Scientific, UK) 
Syringes (Fisher Scientific, UK) 
Universal bottles, glass funnel and  sterile spatula 
Clear bottom white 96 well plates (Grenier, UK). 
 
3.7.1 Chemicals and Reagents in cell culture 
Chemicals and reagents used for cell culture are described in this section.  
 Ethanol and Methanol (Fisher Scientific, UK) 
 Phosphate Buffered Saline-2 tablets was dissolved in 400 ml of water and stored 
the solution at 4 °C (Sigma, Aldrich, UK) 
 MTT assay kit (Sigma Aldrich, UK) 
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3.7.2 Composition of medium and supplements required for cell culture 
The essential medium and supplement was DMEM and MEM (Minimal Essential 
Medium), Fotal bovine serum (FBS), trypsin, L-Glutamine, non-Essential Amino Acid 
(NEAA) and sodium pyruvate (All from Lonza, UK). 
The composition requirement for U87-MG was Minimal Essential Medium (MEM-500 
ml), 10% Fetal bovine serum (FBS-50 ml), 2 mM L-glutamine (5 ml), 1% Non-
Essential Amino Acids (NEAA- 5 ml), 1 mM sodium Pyruvate (5 ml) and for SVGp12 
was Eagle‟s Minimal Essential Medium (EMEM-500 ml) and 10% Foetal bovine serum 
(FBS-50 ml).  
  
82 
 
3.8 Cell culture passaging   
Prior to experimentation, air removal was carried out for 10 minutes in a laminar flow 
hood inside the cabinet. Medium, trypsin (sterile) and PBS were removed from the 
fridge freezer 4 °C and then placed in a water bath at 37 °C for 30 minutes to allow 
equilibration.  
3.8.1 Cell culture and passaging of the Primary Glial Cells (U87-MG and SVGP12) 
Cells were encouraged to grow until they were 70-80% confluent, medium was then 
removed from the cultured flask and was washed with Phosphate Buffer Solution (PBS) 
(5 ml for 75 cm
2
 flask and 2 ml for 25 cm
2
 flask) to remove the serum from the cells, to 
prevent inactivation of Trypsin serum. Trypsin solution (2 ml for 75 cm
2
 flask and 1 ml 
for 25 cm
2
 flask) was pipetted in the flask and incubated at 37 °C in an atmosphere of 
5% CO2 in air for 4-5 minutes until the cells started to detach, this was observed at 
intervals under an inverted microscope. The cells were left in trypsin for an appropriate 
length of time to avoid damage. Complete growth medium (2 ml) was then added to the 
flask to inactivate the trypsin and the cells were pipetted up and down to break down 
any large cell aggregates. The cell suspension was removed from the flask into a 15 ml 
centrifuge tube and centrifuged at 1000 r.p.m for 5 minutes. After centrifugation, the 
supernatant was removed and the cells were pelleted at the bottom of the centrifuge 
tube. Density dependent cell pellet, a volume of 1 ml to 2 ml of fresh medium was 
added and properly suspended in the centrifuge tube. Subsequently, the cells were 
incubated at 37 °C in an atmosphere of 5% CO2 in air. Thereafter, the cells were 
examined under an inverted contrast microscope to note their general health and 
confluences. 
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3.8.2 Haemocytometer and cell quantification 
A volume of 20 μl of cell suspension and 80 μl of trypan blue were pipetted into a micro 
centrifuge tube and mixed. The cover slip was placed over the chambers of the 
haemocytometer as shown in Figure 3.8.  
 
A volume of 20 μl of cell suspension was pipetted against each side of the cover slip to 
facilitate the spreading of the suspension into each chamber. The haemocytometer was 
placed onto the stage of an inverted phase contrast microscope and focused on the 
centre 25 squares of one chamber. The number of cells in these squares were then 
counted. These above steps were repeated for the other chambers. 
 
 
 
Figure 3.8 Neubauer Haemocytometer: each large square gives an area of 1 mm2 (1 mm 
x 1 mm) with a depth of 0.1 mm 
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The average number of cells in the centre grid (1 mm
2
) of each chamber was calculated. 
This number was multiplied by 10
5 
to obtain the number of cells per 1 ml of suspension. 
The total number of cells was calculated by multiplying the number of cells per 1 ml by 
the total volume of the cell suspension. Cell numbers were calculated according to 
equation in 3.1.  
 
= Cell number/ml 
 
 
Equation 3.1 Cell number equation to calculate cells/ml 
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3.8.3 Cryopreservation of cells 
Cryropreservation is where a cell suspension is obtained during passaging and cells are 
allowed to be stored for longer periods in liquid Nitrogen. In this process the cells were 
supplemented with a cryoprotactant which prevents the cells from rupture due to 
formation of ice crystals are slowly frozen down in culture medium. The most important 
principle involves freezing the cells between a range of 1-3 
o
C and then defrosting 
quickly in a 37 °C water bath. Dimethyl sulphoxide (DMSO) is one of the most 
commonly used cryoprotectant. The frozen cell suspension contained of 10% DMSO, 
yield approximately more than 1 million cells. The frozen vial container was in a bath of 
Isopropanol named “Mr. Frosty”, which mediated a 1 oC/minute cooling of the 
cryovials in a – 80 oC freezer prior to storage at a temperature below -135 oC in either 
vapour or liquid phase nitrogen.  
3.8.4 Growth curve  
Demonstration of a standard growth curve for Glioma cell was established when the 
master flask was passaged and cell count was noted. Approximately, 0.23 x 106 (day-0) 
cells were taken and were seeded in five sub flasks. The sub flasks were incubated at 37 
ºC in 5% of CO2 incubator. Each sub flask was passaged on regular basis from day-1 
until day-6 and the cell count was noted down.  
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3.9 Plating of cell lines  
Cell suspensions of U87-MG, and SVGp12 were acquired during passaging and were 
diluted in 1:10 ratio of cell suspension media. The amount of fresh medium and cell 
suspension were calculated based on cell counts. The dilutions were made till 200 μl 
suspensions consisted of 5000 cells. 200 μl of suspension was added into each well on 
96 well plates. Thereafter, the plates were incubated at 37 ºC for 24 hours in 5% CO2 
incubator. The media in the plates were removed on sterile tissue paper. To each well 
100 µl of sample and 100 µl of media was added. PTX and/or CNTs solutions were 
added to the wells and incubated in 5% CO2 incubator at 37 ºC for another 24 hours and 
48 hours. The suspension from the plates was again removed and all the plates were 
washed with 1 x PBS (7.4 pH). Plates were treated according to Figure 3.9 and the 
sample description is given in section 3.9.1.  
To each well of the 96 well plates, a volume of 100 µl of sample and 100 µl of media 
was added, subsequently the plates were incubated at 37 ºC for 24 and 48 hours in 5% 
CO2 incubator. The suspension from the plates was again removed after 24 and 48 hours 
and all the plates were washed with 1 x PBS (7.4 pH) where MTT assay was ready to be 
performed.  
 
3.9.1 Plating of cells with PTX-f -CNTs  
Appropriate amounts of PTX was added to the S1 to S8, the suspensions were sonicated 
for 6 hours and centrifuged for 5 minutes at 1000 rpm. The samples were washed with 
PBS 7.4 pH and were put in the shaker for 6 hours. Then an amount of 100 µl of sample 
and 100 µl of media was added, subsequently the plates were incubated at 37 ºC for 24 
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and 48 hours in 5% CO2 incubator. After 24 and 48 hours the plates were removed for 
the incubator and suspension was aspirated from the plates and washed with 1x PBS.  
 
Figure 3.9 Schematic view of a 96 well plate with recorded samples (a) without PTX 
and (b) with PTX, where; C is CONTROL, S is SAMPLE, MT is no cells and CELL is 
untreated seeded cells 
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Table 3.7 Samples  and controls description used for plating of SVGp12 and U87-MG 
on the 96 well plates with PTX 
 
Control labels Samples 
1c  SWNT  
2c  MWNT  
3c  PEG 400 
4c  PF127 1% 
5c  SWNT-PTX 100 
6c  SWNT-PTX 150 
7c  SWNT-PTX 200 
8c  SWNT-PTX 250 
9c  PTX-100 
10c  PTX-200 
11c MWNT-PTX 100 
12c MWNT-PTX 150 
13c MWNT -PTX 200 
14c MWNT-PTX 250 
15c PTX-150 
16c PTX-250 
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The capacity of each well is 200 µl for each set of experiment; four 96 well plates were  
prepared for PTX of each concentration of 100-250 µg/ml. The total quantity is shown 
in Table 3.8. 
 
Table 3.8 Control labels have been described for each sample with and without PTX 
Samples (with and without PTX) 
1= 1:5             2= 1:1  
Quantity needed for cell culture per 
96 well plate (0.200 µl) 
S1 =  SWNT- PEG 1  2.4 ml  
S2 =  SWNT-PEG 2 2.4 ml 
S3 = MWMT-PEG 1  2.4 ml 
S4 = MWNT-PEG 2  2.4 ml 
S5 = SWNT-PF127 1 2.4 ml 
S6 = SWNT-PF127 2 2.4 ml 
S7 = MWNT -PF127 1 2.4 ml 
S8 = MWNT -PF127 2 2.4 ml  
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Plates were prepared, seeded and cytotoxicity was measured according to the following 
plate structures:  
 
PLATE I  
 
1. SGVp12 at 105cells/well  Plates were seeded as per lay out subsequent 
incubation for 24 hours  
2. Controls were added and drugs at appropriate concentrations in medium 
3. Cells were incubated for 24 hours as per standard tissue culture 
4. Media were removed and cells were subsequently washed with PBS 
5. 180 µl of media was added and MTT assay was performed by the addition of 20 
µl and left for 2 hours 
6. The assayed media was discarded and MTT was added in each well to dissolve 
the crystals of dye 
7. Plates were read at 492 nm wavelength 
PLATE II  
1. SGVp12 at 105cells/well  Plates were seeded as per lay out  subsequent 
incubation for 24 hours 
2. Controls were added and drugs at appropriate concentrations in medium 
3. Cells were incubated for 48 hours as per standard tissue culture 
4. Media were removed and cells were subsequently washed with PBS 
5. MTT assay was performed by the addition of 20 µl and left for 2 hours 
6. The assayed media was discarded and 200 µl of acidified Isopropanol (0.33%v/v 
HCl in Isopropanol) was added in each well to dissolve the crystals of dye 
7. Plates were read at 492 nm wavelength 
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PLATE III  
1. U87-MG at 105cells/well  Plates were seeded as per lay out  subsequent 
incubation for 24 hours 
2. Controls were added and drugs at appropriate concentrations in medium. 
3. Cells were incubated for 24 hours as per standard tissue culture 
4. Media were removed and cells were subsequently washed with PBS 
5. MTT assay was performed by the addition of 20 µl and left for 2 hours 
6. The assayed media was discarded and 200 µl of acidified Isopropanol (0.33%v/v 
HCl in Isopropanol) was added in each well to dissolve the crystals of dye 
7. Plates were read at 492 nm wavelength 
PLATE IV 
1. U87-MG at 105cells/well  Plates were seeded as per lay out  subsequent 
incubation for 24 hours 
2. Add Controls and drugs at appropriate concentrations in medium 
3. Controls were added and drugs at appropriate concentrations in medium. 
4. Cells were incubated for 48 hours as per standard tissue culture 
5. Media were removed and cells were subsequently washed with PBS 
6. MTT assay was performed by the addition of 20 µl and left for 2 hours 
7. The assayed media was discarded and 200 µl of acidified Isopropanol (0.33%v/v 
HCl in Isopropanol) was added in each well to dissolve the crystals of dye 
8. Plates were read at 492 nm wavelength 
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3.10 MTT assay 
MTT assay is the most popular colorimetric assay in which the compound 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide is converted by 
mitochondrial enzymes to a coloured insoluble formazan product, which is solubilised 
in alcohol or detergent followed by absorption measurement. The amount of colour 
produced is proportional to the number of live cells. This assay has been used by many 
investigators as a reliable method of chemosensitivity testing in malignant Gliomas 
(Ferrari, et al., 1990).  
 
Values obtained were expressed as a percentage of control cells to which no formulation 
were added, and comparison was made between f-CNTs-PTX complexes and Control 
(C) samples. Based on the results of the test, the IC50 doses (the concentrations which 
kill 50% of cells) were calculated.  
3.10.1 MTT assay protocol  
1. Media was removed and cells were washed with PBS  
2. PBS was filtered and sterilised to prepare MTT solid and 3 ml of filter PBS  
3. 90 µl of filtered medium was added to 10 µl of MTT which was made up to 3 ml 
of medium and added to each well (96 well plate would require 9 ml of media 
and 1 ml of diluted MTT) 
4. Samples were incubated for 2 hours at 37 0C 
5. The dish was foiled wrapped as a result of MTTs sensitivity to light  
6. Medium was not discarded from the wells. A 100 µl of the clear solubilisation 
reagent in the kit was added  
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7. The plates were agitated at 240 rpm for 10 minutes to enhance dissolution and 
measure absorbance at 590 nm 
3.11 Statistical analysis 
The results were expressed as the mean ± Standard Deviation (SD) from three 
independent experiments and were analysed using the software SPSS 14.0 and 
Graphpad Prism 6.0 to calculate the significance between groups. A difference was 
considered to be significant if the P-value was less than 0.05. 
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CHAPTER 4 
CHARACTERIZATION of PRISTINE 
& FUNCTIONALIZED CNTs 
 
(RESULTS AND DISCUSSION) 
 
 
“The aim of argument, or of discussion, should not be victory, but 
progress” 
(Joseph Joubert)
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CHAPTER 4 
4.1 Characterization and functionalization 
A wide range of techniques have been used to characterize the morphology and 
structures of the materials utilized in this research. Two different types of CNTs with 
various characteristics have been studied, including SWNTs and MWNTs. These have 
been characterized for structure and impurities. MWNTs and SWNTs were also 
functionalized in order to improve their solubility in aqueous solvents using two 
polymeric systems polyethylene glycol (PEG) and Pluronic 127®. The samples were 
homogenised and sonicated. The results presented are Pristine (p-CNT) before and after 
sonication and after filtration.  
The first section covers Raman spectroscopy which provides qualitative data in relation 
to the impurities and structure of CNTs. Thereafter TEM micrographs are shown for the 
samples, followed by SEM, XRD and zeta potential.   
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4.2 Raman Spectroscopy visible 488 nm - Ultra violet 325 nm  
Raman has different characteristic features for analysing CNTs samples. The G-band is 
a feature of the graphite layer which corresponds to the tangential vibration of the 
carbon atoms and second-order related harmonic G‟-band. The D-band sets the sign of 
the typical „defects‟ on the graphite structures. Comparison of the two peak intensities 
gives a measure of the quality of the CNTs. The third feature of Raman spectroscopy is 
the Radial Breathing Mode (RBM) which is sensitive to the diameter of SWNT.  
The RBM is directly dependent on the CNT diameters through the relation shown in 
Equation 4. 1: 
 
 ωRBM = A/dt+B 
Equation 4. 1 Equation for the diameter calculation of SWNTs 
 
Where dt  is the CNT diameter, A and B parameters can be determined experimentally 
(Jorio, Pimenta et al. 2003). For this Raman study A is 234 cm-1 and B is 10 cm-1 this 
is an estimate to the correction of the breathing mode restoration due to tube-tube 
interaction within the bundles (Milnera, Kurti et al. 2000).  
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4.2.1 Raman spectra SWNT  
The Raman spectrum of SWNT has been illustrated in Figure 4.1. The D-band is visible 
in between 1200-1500 cm-1 and confirms the scattering from a defect that breaks the 
basic symmetry in the graphite sheet (Figure4.1(b)). A Shift of 1574 cm-1 is typical for 
G-band of SWNTs (Dresselhaus, Dresselhaus et al. 2005). Also the Radial Breathing 
Mode (RBM) peak is prominent and appears to be in the range of 200 cm-1 and 400 
cm-1. This suggests that the sample that has been investigated can be confirmed to be 
SWNTs and tube diameter can be determined.  
 
 
 
 
Figure 4.1 (a) Raman Spectra of SWNT with Ar + laser (488 nm) the peak marked with 
* is Hg calibration peak (b) expanded spectra of D-band (c) Expanded spectra of second 
order G‟-band. 
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Figure 4.1 (c) is the second order G‟-band and is identified as a higher order peak of the 
D-band featured at 1390 cm-1 (Figure 4.1(b)) (Dresselhaus, Dresselhaus et al. 2005).  
In Figure 4.2 the low frequency of 200-400 cm-1 region spectra has been shown and 
frequencies of 236, 255, 297, 324, 332 and 359 have been observed, whereby the tube 
diameter was calculated.  
 
 
Figure 4.2 Room temperature Raman spectrum of SWNT on the expanded scale show 
the details of RBM and tube diameter (nm)  
 
The tube diameter is calculated and is presented in Table 4.1 and the diameter of the 
SWNT have been plotted against the RBM frequency showing a linear relationship i.e. 
the higher the RBM frequency the lower the tube diameter as seen in Figure 4.3.  
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Table 4.1 Tube diameters calculated from radial breathing mode (RBM) frequencies 
using the relation ωRBM = 234/dt -10 
 
Excitation 
488 cm-1 
ωRBM  (cm-1) dt   (~ nm) 
236 1.03 
255 0.95 
297 0.81 
324 0.74 
332 0.72 
359 0.67 
Average  0.80 
 
 
Figure 4.3  RBM frequencies vs tube diameter (nm) 
 
It is also evident that RBM frequency is diameter dependent. It can be seen that SWNTs 
has diameters ranging from ~ 0.67-1.03 nm providing an average diameter of 0.8 nm.  
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This is in agreement with the TEM micrographs (Figure 4.4) shown in which SWNTs 
are obvious and an estimate of the tube diameter can be concluded from the scale to 
confirm the data observed from Raman Spectra. The length of the SWNTs can be 
confirmed from in which it is to be in the range of 50 ± 250 nm (Figure 4.5). However, 
when morphology of the CNTs where characterized with SEM (Figure 4.6) merely a 
rough estimate of length could be observed.  
 
 
 
Figure 4.4 TEM micrograph of SWNT at x 245000 magnification 
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Figure 4.5 TEM micrographs of SWNT x 65000 magnification 
 
Figure 4.6 SEM micrographs at various magnifications 
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4.2.2 Raman Spectra of MWNT  
Since the geometry, number of walls and tube diameter of MWNTS varies from 
SWNTs; Raman spectra of MWNTs are expected to slightly differ. A typical G-band 
shift of 1578 cm-1 (Figure 4.7) is expected for MWNTs that are synthesized with CVD 
(Lee, Kim et al. 1999).  
 
Figure 4.7 Raman Spectra of MWNT with 488 nm, the peak marked with * is Hg 
calibration peak 
 
No RBM Peak was determined for MWNT in the 200-400 cm-1 range, as this was 
expected and confirmed. This also can be a confirmation that the MWNT samples do 
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not contain any SWNT. Due to the large diameter of MWNTs, the signal of RBM is too 
weak to be observed.  
The D-band at 1385
 
cm-1 (Figure 4.7) is mainly derived from the disordered carbon and 
defects of MWNTs, a feature common to sp
2
 hybridized disordered carbon materials 
(Arbizzani, Righi et al. 2011) that have been utilized through laser excitation of 352 nm. 
Furthermore, the sample has a typical G-band of 1578
 
cm-1, second order G‟-band is in 
the range of 2700-2800
 
cm-1 that is established for MWNT. For MWNTs length 
determination TEM micrographs have been utilised. Sample contained various tube 
lengths ranging from 50-1000 nm with an average of 580 nm (Figure 4.8).With higher 
magnifications (Figure 4.9) the nature of MWNT becomes clearer. The inner and outer 
diameters was determined and found to range from ± 10-20 nm Inner diameter (I.D) and 
± 30-40 nm Outer diameter (O.D). CNTs were arranged in a concentric arrangement 
and in one MWNT 8 walls can be counted showing 4 concentric CNTs of increasing 
diameter. Nevertheless, it is of great difficult to identify their precise structure through 
SEM (Figure 4.10).  
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Figure 4.8 TEM micrograph of MWNT x33000 magnification 
 
 
 
Figure 4.9 TEM micrograph of MWNT at x180 000 magnification 
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Figure 4.10 SEM micrograph of MWNTs with various magnifications 
 
4.2.3 Raman comparison of SWNT and MWNT 
 
As stated earlier, CNTs are made up of graphene rolled up into a tubular geometry. 
MWNTs contain a number of sheets rolled in a concentric manner with a range of 
diameters in the nanometre range. MWNTs elicited a wider range of outer diameters. 
Therefore the Raman spectra for MWNTs are not as distinct compared to that of 
SWNTs. For example, RBM signal (Figure 4.11) is normally too weak to be observed 
as it gives an average diameter which broadens the signal (Costa, Borowiak-Palen et al. 
2008).   
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Figure 4.11 Raman Spectra of MWNT and SWNT with 325 nm  
 
It is clear that the G-band for MWNT is small in intensity comparing to SWNT, this can 
be related to the diameter distribution within the individual MWNTs. An alternative 
explanation is the variation between the tubes. The D- and G-bands confirm 
investigation of the „defects‟ on CNTs. When these two bands present similar intensity, 
this indicates a high quantity of „defects‟. On examination it was seen that MWNTs had 
similar intensities, meaning high quantity of structural defects due to its multilayer of 
graphite sheets.  
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4.2.4 Raman spectra of pristine and f-CNTs  
Raman spectra of dispersed SWNTs showed a significant G-band peak shift confirming 
the presence of the surfactants that were utilised to functionalize the CNTs (Figure 4.12 
Figure 4.12). The D- and G-bands shifts confirmed investigation of the „defects‟ on 
CNTs. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.12 Raman Spectra of functionalized CNTs 
Similar intensity presented by these two bands indicated a high quantity of „defects‟. 
Evidently MWNTs had similar intensities suggesting high quantity of structural defects 
due to the multilayer of graphite sheets, there was significant change in the D-bands for 
both SWNTs and MWNTs that were functionalized with the two polymeric systems. 
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The decrease of the Raman intensity of G-band and increase of D-band observed for the 
functionalized CNTs could be attributed to a change in the electronic properties and/or 
an alteration of the vibrational modes of the tubes (Figure 4.12). 
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4.3 X-ray diffraction for sample purity  
X-ray diffraction (XRD) is a non-destructive method for characterising CNTs. The 
technique gives information about interlayer spacing, structure and impurities.  
Arrangements of CNTs were random; however diameter and chirality could be 
determined. The XRD of CNTs is similar to graphite. A peak at (002) can be used to 
obtain the interlayer spacing a family of (hk 0) peaks due to the honeycomb lattice of 
single graphene sheet. However, in this study XRD is not used to determine the micro 
structural details but to provide information about sample impurities (catalyst and 
functional group). Data comparison between MWNTs and literature has been illustrated 
in Figure 4.13. 
 
 
 
Figure 4.13 XRD spectra of MWNTs (left) from this study and (right) from (Belin and 
Epron 2005) 
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MWNTs in this study and those from literature were synthesised using chemical vapour 
deposition method, both samples showed a (002), (100) and (004) peaks, however in 
this study there was an absence of additional peaks. This suggests that the sample in this 
study is of high purity free from catalyst impurities. Similarly, a comparison of spectra 
has been shown for SWNTs in Figure 4.14 and they exhibits similar peaks and were 
also free from impurities. The graphite spectrum is also shown for comparison. 
 
 
Figure 4.14 XRD spectrum of SWNTs (left) and Graphite (right) in red line 
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4.4 Functionalization and comparison of aqueous stability of CNTs 
with Polyethylene glycol 400 and Pluronic 127  
Functionalization of CNTs has been established using PEG400 and PF127; and 
comparison has been conducted before and after sonication and homogenisation (Figure 
4.15). TEM and SEM micrographs were taken to characterise the dispersion. 
Furthermore, ζ-potential was measured to note the aqueous dispersion stability. 
Additionally to confirm the presence of the f-CNTs, Raman spectra were recorded.  
 
 
 
Figure 4.15 SWNT and MWNT in PEG400 and PF127 (a) SWNT (left) and MWNT 
(right) in PEG400, (b) dispersion of SWNT (left) and MWNT (right) in PF127 prior 
homogenising and sonication 
 
Clearly SWNTs show a better dispersion in both polymeric systems prior to any mixing. 
Dispersion improvement was seen Figure 4.16 in after 10 minutes sonication, however 
the dispersion is unstable and particles were visibile, it is not uniformly dispersed. 
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Figure 4.16 Shows the dispersions of SNWTs after 10 minutes ultrasonication 
 
 
After the desipersion were sonicated for 1 hour and filtration was achieved, a significant 
difference was noted (Figure 4.17). Both SWNTs and MWNTs show a better dispersion 
in PEG400 in comparison to the dispersion in Figure 4.15.  
  
 
 
Figure 4.17 MWNT (left) and SWNT (right) in PEG 
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To confirm the uniformity of the dispersions of PEG400 with SWNTs and MWNTs, 
TEM micrographs were taken. As it can be seen in Figure 4.18, SWNTs in PEG400, 
show a clear uniform dispersion.  
 
 
Figure 4.18 TEM Micrographs of f-SWNT in PEG400   
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From the Raman spectra in Figure 4.19 no significant G-band shift was observed. 
However, there is a significant decrease of D-band indicating the degree of disorder 
present in the nanotube. The new peak of D-band at 1375 cm-1 confirms modified 
SWNTs. 
 
Different intensity of the G-band of f-MWNTs with PEG (Figure 4.20) was observed, as 
well as a shift difference of 35 cm-1 that changed from 1575 cm-1 to 1540 cm-1 during 
the functionalization process as an enhancement of defects was expected, which 
subsequently supports the attachment of molecules (Rajalakshmi, Ryu et al. 2005). 
Moreover, a significant higher intensity was observed in the D-band, which is due to its 
multilayer graphite sheet modification.  
 
Figure 4.19 Raman spectra showing a shift and decrease in intensity of f-SWNT 
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Figure 4.20 Raman spectra of f-MWNT in PEG 
 
Nevertheless, not all CNTs concentrations achieved a uniform dispersion in PF127 as 
can be noticed in Figure 4.21.  
 
Figure 4.21 MWNT (left) and SWNT (right) in PF127 
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Concentration of 1:5 MWNTs was shown to be the least dispersed. However, both 1:1 
and 1:5 concentration of SWNTs in PF127 demonstrated a homogenised dispersion 
presented a number of different trends (Figure 4.22 and Figure 4.24). 
 
 
Figure 4.22 Raman spectra of p-SWNT and f-SWNT-PF127 
 
 
Figure 4.23 SEM micrograph of f-SWNT-PF127 
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From MWNT, merely 1:1 ratios to PF127 showed a better dispersion and this in 
agreement with the Raman spectra in Figure 4.24. For example the D-band peak for f-
MWNT-PF127 1:1 ratio elicited substantially greater Raman intensity than its 
counterpart formulations; this may be explained by changes within the surface of the 
formulation specifically the CNT component. 
 
Raman spectra of f-MWNT–PF127 were reordered and shifts were observed for both 
concentrations. However, a more prominent shift was seen with the 1:1 ratio, this may 
be due to the CNT surface and surfactant interaction.  
 
 
Figure 4.24 Raman spectra of p-MWNT and f-MWNT-PF127 
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4.5 ζ-potential   
To evaluate the CNTs conjugates further with regards to their surface charges and 
functional groups, zeta potential analysis has been performed. The zeta potential of a 
system gives an indication of its stability. When particles in a solution have a large ζ - 
potential, whether positive or negative, they will repel each other and will not aggregate 
together. Low zeta potential infers low repulsive forces to push the particles apart and 
therefore they will tend to aggregate together. The zeta potential measurements are 
essential for CNTs in drug delivery to monitor their stability and to determine their 
behaviour. The ζ- potential records of pristine (p) and functionalized CNTs are 
presented in Table 4.2  
 
Table 4.2 ζ-potential Mean ± SD of Pristine and f-CNTs 
Concentrations / 
MWNT/SWNT 
ζ-potential  Mean 
± SD  
ζ-potential  after 10days  
Mean ± SD  
p- MWNT  -9.47 ± 0.3 -9.57 ± 0.3 
MWNT-PEG 1:1 -20.00 ± 0.2 -18.47 ± 0.4 
MWNT-PF127 1:1 -15.40 ± 0.4 -15.61 ± 0.7 
MWNT-PEG 1:5 -22.23 ± 0.5 -19.60 ± 1.5 
MWNT-PF127 1:5 -12.00 ± 0.6 -8.67 ± 0.8 
p-SWNT  -7.81 ± 0.25 -7.81 ± 0.9 
SWNT-PEG 1:1 -19.30 ± 0.6 -19.3 ± 0.6 
SWNT-PF127 1:1 -13.10 ± 0.4 -11.8 ± 1.6  
SWNT-PEG 1:5 -17.30 ± 0.4 -15.3 ± 0.8 
SWNT-PF127 1:5 -15.30 ± 0.3 -16.8 ± 1.6 
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ζ-potential of p-CNT were presented to be -7.81 mV for p-SWNTs and -9.47 mV for p- 
MWNTs, with PEG400 -20.0 mV for SWNTs and -19.3 mV for MWNTs and with 
PF127 -13.10 mV for SWNTs and -15.4 mV (Figure 4.25). 
 
Interestingly, no significant difference was observed in the two concentrations of p-
SWNTs and p-MWNTs. However, there was significant difference between the p-CNTs 
and f-CNTs for both surfactants at any given ratio (p<0.05). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.25 ζ-potential of pristine CNTs (p-CNT), CNT-PEG and CNT-PF127 were 
demonstrated. The error bars represent the standard deviation (SD) of three samples 
 
On carrying out a multiple comparison test, a significant difference between SWNT-
PEG 1:1 and MWNT PF127 1:1 (p<0.05) was observed. In order to show a difference in 
ζ-potential for all formulations, samples were left to settle and measurements were 
repeated after 10 days.  
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As shown in Figure 4.26, no significant difference was observed for SWNTs freshly 
prepared and measurements after 10 day.  
 
 
 
 
 
 
 
Figure 4.26 ζ-potential of SWNT in PEG and PF127on preparation day and after 10 
days. The error bars represent the standard deviation (SD) of three samples 
 
 The graph presented in Figure 4.27 shows the ζ - potential of freshly prepared and after 
10 days samples of p-MWNTs and f-MWNTs. Measurements after 10 days showed no 
significant between p-MWNTs immediately and after 10 days. However, there is a 
significant difference between all the formulations when compared to one another 
(p<0.05). Only PF127 ratios showed no significant difference when compared in ratios 
and with p-MWNTs.  
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Figure 4.27 ζ-potential of MWNT in PEG400 and PF127 on the preparation day and 10 
days after. The error bars represent the standard deviation (SD) of three samples 
 
Moreover, a comparison of both SWNTs and MWNTs has been plotted in Figure 4.28, 
with both surfactants showing that MWNT-PF127 ratio 1:5 after 10 days has 
significantly lower ζ-potential than any presented formulation, at any ratio and time 
(p<0.05). To elaborate more and to confirm that all samples were of acceptable quality, 
a phase plot was conducted and it showed to be satisfactory (Figure 4.29). 
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Figure 4.28 ζ-potential of SWNT and MWNT in PEG and PF127 1% on preparation 
day and 10 days after. The error bars represent the standard deviation (SD) of three 
samples 
Figure 4.29 Phase plot that shows the quality of the samples used for ζ-potential 
measurement 
 
In conclusion the characterization of the samples of both SWNT and MWNT in PEG 
has been shown to be significantly more dispersed and achieved a maximal decrease in 
Raman intensities as well as shifts in the G-bands; furthermore it also appears to be 
most stable as the ζ-potential shows a high charge (p<0.05). 
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4.6 Paclitaxel f-CNTs  
Determination of the Entrapment Efficiency (EE%) of PTX, was established through 
the conduction of a calibration curve that was measured from the stock solution. 
Thereafter, the formulations wer analysed with HPLC to define their entrapment 
efficiency using the respective linear regression equation.  
4.6.1 Calibration Curve  
Calibration curve of Paclitaxel concentration ranging from of 50-250 ug/ml was plotted 
using HPLC. The plot was used to obtain the equation R
2
 for Paclitaxel; this is shown in 
Figure 4.30. Observably, a good linear relationship (r = 0.9997) was established. As the 
concentration increases there is a linear increase in absorbance. Using the respective 
linear regression equation y = 655679x + 209811, the entrapped Paclitaxel with CNTs 
can be found 
 
Figure 4.30 Paclitaxel calibration curve 
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4.6.2 Entrapment efficiency of f-CNTs 
Loading efficiency of paclitaxel in the CNT- Surfactant was dependent on type of 
CNTs, surfactant and concentrations of drug. For this experiment a One-way ANOVA 
statistical test has been used where p<0.05 is considered as significant. With the below 
equation the entrapment efficiency was calculated. 
 
 
 
The entrapment efficiency of the formulations is demonstrated in Table 4.2 and it was 
found that PTX concentrations of 200 µg showed significantly (p<0.001) higher 
percentage entrapment for f-CNTs in comparison to 100 µg, 150 µg and 250 µg 
concentrations. However, p-CNTs entrapment percentage showed to be concentration 
dependent, and had achieved maximum entrapment efficiency with PTX of 200 µg/ml. 
(Calculated drug content) 
%EE=             ×100    
(Theoretical drug content) 
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 Table 4.2 Entrapment efficiency of pristine (p) and functionalized (f) CNTs 
f-CNTs 
Entrapment efficiency in % ± µg/ml  
PTX 100 µg PTX 150 µg PTX 200 µg PTX 250 µg 
p SWNT 7.45 ± 7.4 13.35 ± 20.0 25.11 ± 50.2 32.92 ± 82.3 
SWNT PEG 1:1 12.15 ± 12.1 27.07 ± 40.6 71.33 ± 142.7 39.38 ± 98.5 
SWNT PEG 1:5 12.45 ± 12.5 29.65 ± 44.5 87.56 ± 175.1 41.94 ± 104.8 
SWNT PF127 1:1 15.27 ± 15.3 31.16 ± 45.7 86.23 ± 172.5 52.30 ± 130.8 
SWNT PF127 1:5 15.23 ± 15.2 32.03 ± 48.1 87.24 ± 174.5 49.92 ± 124.8 
p MWNT 14.02 ± 14.0 32.19 ± 48.3 46.29 ± 92.6 57.54 ± 143.9 
MWNT PEG 1:1 12.27 ± 12.3 27.11 ± 40.7 72.74 ± 145.5 40.13 ± 100.3 
MWNT PEG 1:5 12.99 ± 13 11.58 ± 17.4 17.55 ± 35.1 41.91 ± 104.8 
MWNT PF127 1:1 14.68 ± 14.7 31.09 ± 46.6 85.94 ± 171.9 50.47 ± 126.2 
MWNT PF127 1:5 15.18 ± 15.2 31.44 ± 47.2 86.42 ± 172.8 50.65 ± 126.6 
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The entrapment efficiency expressed as a percentage of the total concentration of PTX 
for p-MWNT and p-SWNT is shown in Figure 4.31. 
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Figure 4.31 Entrapment efficiency of p-MWNT and p-SWNT 
 
As the concentration of PTX is increasing from100 µg/ml to 250 µg/ml the entrapment 
efficiency increases linearly in both cases for p-MWNTs and p-SWNTs. For p-SWNTs 
the entrapment efficiency increases by a factor of 5 from 7% to 33%, whereas for p-
MWNTs the increase is less prominent by a factor of 4.1. However, the entrapment 
efficiency is considered very significant and is approximately double that of p-SWNTs 
(p<0.001). The trend is as expected, and when MWNTs are used there is more space to 
entrapment for the drug onto the nanotubes. The PTX is attached to the outer surface of 
the CNTs. TEM micrographs shown the outer diameter (O.D.) of SWNT is in between 
15-20 nm and the MWNT is between 30-40 nm. The diameter of MWNT is twice the 
size of SWNT. Hence, we can conclude that the entrapment efficiency of PTX increases 
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with the outer diameter of CNTs. However, further investigation would be required to 
verify this theory. 
The entrapment efficiency of SWNTs (Figure 4.32) has been demonstrated and was 
observed that for SWNTs concentrations, highest entrapment efficiency were only 
achieved with 200µg/ml. The MWNTs formulations also show similar behaviour in 
Figure 4.33 .  
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Figure 4.32 Entrapment efficiency of f-SWNT 
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Figure 4.33 Entrapment efficiency of f-MWNT 
 
The bar representing the formulation MWNT-PEG 1:5 has not been carried out in 
calculations as results were anomalous (Figure 4.34). For a significant difference 
between concentration 200 µg/ml Vs. formulations, the Bonferroni's multiple 
comparisons test has been carried out for all concentrations. Significantly higher 
entrapment efficiency was achieved with SWNT-PEG 1:5 and SWNT-PF127 ratios 1:5, 
respectively (p<0.05).  
 
To understand the correlation between the PTX concentrations and CNTs a graph has 
been plotted for all formulation (Figure 4.34). 
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Figure 4.34 Paclitaxel f-CNTs and their entrapment efficiency 
Entrapment efficiency has been plotted against PTX concentrations for all formulations 
investigated. The trends for all formulations were similar with the curves being bell 
shaped. Whilst the majority of formulations followed a set trend an anomaly was 
observed in the form of the curve generated by MWNT-PEG 1:5. The curve generated 
for this combination is significantly different from of other formulations. There are a 
number of different possible explanations for this. There is a very significant difference 
when all concentration compared to one another (p<0.001). Also a significant difference 
was observed within the formulations (p<0.05). In all CNTs formulations the 
entrapment efficiency has increased as the PTX concentration has increased achieving 
the maximum entrapment efficiency of 200 µg/ml. Thereafter, a negative trend was 
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observed for all formulations containing PTX. Peak entrapment efficiency of 200 µg/ml 
PTX is shown in Figure 4.35. 
 
 
Figure 4.35 Entrapment efficiency achieved with all formulations at 200 µg/ml; the bar 
represent with * is anomalous and not calculated with other formulations 
 
When SWNTs are compared, as expected the addition of both surfactants PEG and 
PF127 to the CNTs increases the entrapment efficiency. As the amount of PEG is 
increased the entrapment efficiency increases form 71.33% to 87.56%. The addition of 
PEG at a ratio of 1:1 increases the entrapment efficiency from 25% to 71%, 
representing a 3 fold increase. The results suggest a stoichiometric effect due to non- 
covalent bonding of the surfactant onto the walls of CNTs and only as for the PTX 
molecules in solution. However, further work is required to investigate and verify this 
hypothesis. 
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4.6.3 Saturation effect 
From Figure 4.34, maximum entrapment efficiency was reached at 200 µg/ml, 
thereafter a decreasing trend was observed. As constructed in Figure 4.36 the 
concentration increases when surface side of the CNTs become occupied by surfactants 
or PTX and thus all the sides are saturated. Further increases of concentration results in 
collision behaviour to PTX in solution and the non-covalently attached PTX, the CNTs 
carry it to desorb. 
This process of detachment of PTX from CNTs increases these results in decreasing of 
entrapment efficiency.  
 
Figure 4.36 Correlation of SWNTs and MWNTs against PTX concentrations 
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 4.7 Conclusions  
The characterization and functionalization of both SWNTs and MWNTs using various 
techniques has been presented. Results confirmed and showed that samples were 
utilized in this study were SWNTs and MWNTs. It was concluded that SWNTs have 
diameters ranging from 0.67 ± 1.03 nm (p<0.05) which is in agreement with small CNT 
diameter that are favourable for studies for biomedical applications (Yang, Thordarson 
et al. 2007).  
Also an establishment was confirmed that CNTs were functionalized with two different 
biocompatible surfactants, including PEG400 and PF127 and their ζ-potential were 
measured for their stability. The decrease of the Raman intensity of G-band and increase 
of D-band were observed for the functionalized CNTs were due to a change in the 
electronic properties and/or an alteration of the vibrational modes of the tubes.  
Loading efficiency of Paclitaxel onto CNT-Surfactants was dependent on the type of 
CNTs, surfactant and concentrations of drug. However, PTX entrapment percentage 
showed concentration dependency, and to have reached the maximum entrapment 
efficiency at 200 µg/ml.   
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CHAPTER 5 
 
In Vitro Cytotoxicity of f-CNTs 
(RESULTS AND DISCUSSION) 
 
„‟Science never solves a problem without creating ten more‟‟ 
(George Bernand Shaw)
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CHAPTER 5 
5.1 In Vitro Cytotoxicity  
Various types of CNTs have been utilised for in vitro studies in cancer treatment. Its 
purpose was to achieve a greater decrease of cellviability in cancer cells in combination 
of drug CNTs formulations. Paclitaxel (PTX) is an anti-cancer drug that has been used 
for various types of cancer. The purpose of cytotoxicity test is to assess the effect of 
PTX, f-CNTs and PTX-f-CNTs and compare between the concentrations and types of 
CNTs. 
In this chapter, cell culture studies are demonstrated and related results are presented. 
Two cell lines were investigated in order to analyse cytotoxicity; including SVGp12 
(normal human brain cells known as astrocytes) and human glioblastoma-astrocytoma 
grade IV Glioma cells (U87-MG). Cell density selection was based on cell growth 
curves that was generated and curve line were established for both cell lines. Cell 
viability in percentage was analyzed with the following equation: 
 
 
 
Data was analyzed and p<0.05 was found for treated cells compared to untreated 
(controls), which was considered significant. Statistical analysis were performed using 
One-way ANOVA followed by Tukey‟s multiple comparison test (to compare all 
groups) or Two-way ANOVA followed by Bonferroni‟s multiple comparison test 
(Pristine and Functionalized CNTs and PTX various concentrations). 
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5.2 Growth curve of cell lines  
For both cell lines, varied densities were assessed ranging from 10
3
-10
5
 cells/well. Cells 
were seeded and allowed to grow for seven days and their densities were of 10
3
, 10
4
 and 
10
5 
cells/well. Each day their absorbance was measured. Measurements values in 
between 0.7-0.9 (pure media) were expected for appropriate seeding densities. This 
information was needed to perform the cytotoxicity assay and identify the effect.   
5.2.1 Growth curve of SVGp12 
The absorbance values for the growth curves of SVGp12 cell lines were significantly 
different for all three seeding densities measured each day (p<0.05). Their seeding 
densities were plotted and it was observed in microscopic picture of cell density of 10
5 
(Figure 5.1). 
Density of 10
3
 cells/well increased to nearly 198 ± 6.56% and the absorbance readings 
were in the range of 0.1-0.15 units at day 7. Whereas, density of 10
4
 cells/well was 
increased to 251 ± 7.5%, however the absorbance readings were in the range of 0.3-0.33 
units. Subsequently, once 10
5
 cells/well density reached 260 ± 8.9% and their 
absorbance values in the range of 0.78-0.81 units. 
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Figure 5.1 (a) Growth percentage of SVGp12 from three densities and (b) microscopic 
picture of 10
5
 cell/well (x100) 
 
5.2.2 U87-MG growth curve  
 
Significant differences were observed for all three densities 10
3
,10
4
 and 10
5 
(p<0.05). 
According to Figure 5.2(a), highest cell absorbance in the range of 0.92-0.96 units and 
approximate cell growth of 301 ± 6.6% was achieved through 10
5
 cells/well density at 
day 6. This also is in agreement with the microscopic picture shown in Figure 5.2(b). In 
contrast, the growth for 10
3
 and 10
4
 cells/well densities at day 6 demonstrated values in 
the range of 0.16-0.19, 0.31-0.35 units with cell growth of 240 ± 5.6% and 285 ± 6.5%, 
respectively. The images were in accordance with growth curves obtained via the 
absorbance readings as the number of cells per well is directly proportional to the 
absorbance or cell viability. 
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Figure 5.2 (a) Growth percentage of U87-MG from three densities and (b) microscopic 
picture of 10
5
 cell/well density (x100) 
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5.3 Effects of PTX on SVGp12 and U87-MG  
To measure the effect of PTX on SVGp12 and U87-MG grade IV glioblastoma, cells 
were treated for 24 and 48 hours, respectively. Data obtained are expressed as mean% ± 
SD, n = 3 and p-value of <0.05 for untreated (control) compared to treated cells are 
demonstrated.  
5.3.1 Effect of PTX concentrations of SVGp12  
 
SVGp12 cell lines were treated for 24 and 48 hours with four different concentration 
ranging from 100-250 µg/ml. Evidently, there was a decrease of cell viability and 
showed to be PTX concentration dependent (Figure 5.3).  
 
Figure 5.3 The effect of different PTX concentrations on SVGp12 cell line. The error 
bars represent the standard deviation (SD) of three samples 
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Higher rate of cell death was observed with increased concentrations of paclitaxel. 
Significant toxicity was observed for all concentrations and their respective cell 
viabilities. However, cell viability for concentration of 100 µg/ml was 54% ± 2.0 at 24 
hours and 45% ± 2.6 at 48 hours, moreover 250 µg/ml showed cell viabilities of  21% ± 
1.4 at 24 hours and16% ± 1.6 at 48 hours (p<0.05). This was confirmed with 
microscopic pictures shown in Figure 5.4 that were treated for 24 hours and 48 hours 
(Figure 5.5). Minimal viable cells were observed for the highest concentrations of PTX 
(250 µg/ml). 
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Figure 5.4 Microscopic pictures of SVGP12 treated with Paclitaxel for 24 hours (x100) 
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Figure 5.5 Microscopic pictures of SVGP12 treated with Paclitaxel for 48 hours (x100) 
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5.3.2 Effects of PTX concentration on U87-MG  
Dose dependent effect of Paclitaxel on U87-MG cells, showed the influence of different 
Paclitaxel concentrations at 24 hours and 48 hours. 
 
Figure 5.6 The effect of different PTX concentrations on U87-MG cell lines. The error 
bars represent the standard deviation (SD) of three samples 
 
As can be observed from Figure 5.6, an addition of 100 µg/ml of Paclitaxel treated cells 
for 24 hours, cell viability was found to be 64% ± 2.2. Thereafter, the cell viability 
significantly decreased with higher concentrations of Paclitaxel ranging from 150 µg/ml 
with cell viabilities of 42% ± 2.2 and 36% ± 1.2 for 200 µg/ml and for 250 µg/ml 
viability found to be 25% ± 1.4, respectively (p<0.05). No significant difference was 
observed for concentrations in between 200 µg/ml and 250 µg/ml; confirmation was 
established with microscopic pictures shown in Figure 5.7. 
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Figure 5.7 Microscopic pictures of U87-MG different treated with four different 
concentrations for 24 hours (x100) 
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Cells that were treated for 48 hours also showed significant differences in cell viabilities 
for all concentrations, their percentage values were 59% ± 2.2 for 100 µg/ml, 54% ± 2.3 
for 150µg/ml, 41% ± 1.3 for 200 µg/ml and for 250 µg/ml observed cell viability was 
29% ± 1.5, respectively (p<0.05). Significantly higher values were achieved for both 
concentrations 200 µg/ml and 250 µg/ml for comparative strengths that were treated for 
24 hours (p<0.05). This may be attributed to the fast multiplication of cancer cells and 
thus a higher concentration of drug is prudent. Furthermore, there is an extremely 
significant difference for untreated cells and paclitaxel treated cells (p<0.001). 
Moreover, this is also in agreement with the microscopic picture in Figure 5.8. 
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Figure 5.8 Microscopic pictures of U87-MG treated with four different concentrations 
for period of 48 hours (x100) 
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5.4 Effect of pristine CNTs on SVGp12 and U87-MG 
Assessment of pristine (p) CNTs cytotoxicity, including SWNTs and MWNTs were 
examined on both SVGp12 and U87-MG cell lines. Four different concentrations of 
CNTs mg/ml of media were investigated and cells were treated for 24 and 48 hours. 
Data obtained are expressed as mean% ± S.D, n = 3, p<0.05 for untreated (control) 
compared to treated cells. 
5.4.1 Effect of p-CNTs on SVGp12  
Cell viability observations from Figure 5.9 concluded no significant difference between 
p-CNTs and SVGp12. Even at high concentrations of 15 mg/ml, both p-SWNTs and p-
MWNTs cells retained their viability. Although, no significant difference was observed, 
cells treated with p-SWNTs (1mg/ml) for 24 hours, showed minimal increase in cell 
viability (105% ± 2.5). 
Figure 5.9 SVGp12 cell lines treated with pristine CNTs for 24 and 48hours. The error 
bars represent the standard deviation (SD) of three samples 
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Moreover, as expected, various concentrations of p-SWNTs and p-MWNTs showed no 
significant toxicity on SVGp12 cell line. Figure 5.10 shows SVGp12 cells treated with 
p-SWNT and p-MWNT (1 mg/ml) for 24 hours.   
 
 
Figure 5.10 Microscope pictures of p-MWNT and p-SWNT of  SVGp12 treated for 24 
hours (x200)  
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5.4.2 Effect of p-CNTs on U87-MG 
Viability of cell lines U87-MG are shown in Figure 5.11. No significant differences 
were determined for any concentrations when compared to untreated cells. Concluding 
that even at high concentration of 15 mg/ml, p-SWNTs and p-MWNTs showed no 
effect. Nevertheless, p-CNTs presence in cells treated for 24-48 hours were confirmed 
from the microscopic pictures (Figure 5.12).  
 
Figure 5.11 Different concentrations of pristine (p) CNTs (CNTs) on U87-MG cell line. 
The error bars represent the standard deviation (SD) of three samples  
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Figure 5.12 Microscope pictures of p-MWNT and p-SWNT of  U87-MG  (x200) 
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5.5 PTX and p-CNTs cytotoxic effect on SVGp12 and U87-MG  
Comparison between PTX and p-CNTs was carried out on SVGp12 and U87-MG for a 
period of 24 and 48 hours. For this experiment, four different concentrations of PTX 
were utilized. The results are given in mean i.e. mg ± SD, while IC50 represents the 
concentrations of a drug that is required for 50% inhibition in vitro. 
5.5.1 Effect of PTX and p-CNTs on SVGp12 
No significant difference was observed for PTX-p-CNTs in comparison with PTX alone 
for any given concentration (Figure 5.13). However, as expected there is a significant 
difference between PTX concentrations (p<0.05).  
 
Figure 5.13 Cell viability of SVGP12 treated with PTX alone and p-CNT-PTX for 24 
hours. The error bars represent the standard deviation (SD) of three samples  
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On comparison of the effect of p-CNT-PTX and PTX alone, the results show that CNTs 
do not have an effect on PTX concentrations. Even when cells were treated for longer 
period (48 hours), showed no significant difference (Figure 5.14).  
 
Figure 5.14  Cell viability of SVGp12 treated with PTX alone and p-CNT-PTX for 48 
hours. The error bars represent the standard deviation (SD) of three samples 
 
 
The presented values in Table 5.1 shows  IC50 of all formulations and it can be seen that 
6.2 mg (PTX) was required to inhibit 50% of SVGp12. Similar IC50 values were 
observed for PTX-SWNTs (6.4 mg), however 7.3 mg of PTX-MWNTs was necessary 
to inhibit 50% of cells. No significant difference can be observed in between IC50 values 
when compared to one another. 
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Table 5.1 IC50 Values of the formulations in mg for SVGp12 cells   
 
5.5.2 Effect of PTX and p-CNTs on U87-MG 
 
U87-MG cell lines were treated with PTX alone (control) and PTX-SWNTs and PTX-
MWNTs for 48 hours. According to Figure 5.15 cell viability values for concentrations 
150 µg/ml, 200 µg/ml and 250 µg/ml showed no significant difference.  
 
 
Figure 5.15 Cell viability of U87-MG treated with PTX alone and p-CNT-PTX for 24 
hours The error bars represent the standard deviation (SD) of three samples 
Formulations 
IC50 mg ± SD 
SVGp12 (24 hours) 
IC50 mg ± SD 
SVGp12 (48 hours) 
PTX 6.2 ± 1.1 5.7 ± 1.2  
PTX-SWNT 6.4 ± 1.0 6.0 ± 1.0 
PTX-MWNT 7.3 ± 0.8 5.1 ± 1.0 
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Cells treated for 48 hours elicited similar cell viabilities when compared in 
concentrations of PTX alone and in comparison to PTX-SWNTs and PTX-MWNTs 
(Figure 5.16). Moreover, no significant difference was demonstrated in IC50 values no. 
 
 
Figure 5.16 Cell viability of U87-MG treated with PTX alone and p-CNT-PTX for 48 
hours. The error bars represent the standard deviation (SD) of three samples  
 
Table 5.2 IC50 Values of the formulations in mg for U87-MG cells 
Formulations  
IC50 mg ± SD 
U87-MG ( 24 hours) 
IC50 mg ± SD 
U87-MG (48 hours) 
PTX  9.0 ± 1.5  11.0 ± 2.0 
PTX-SWNT 8.8 ± 1.5 7.0 ± 1.5 
PTX- MWNT 5.9 ± 0.5 7.6 ± 1.6 
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5.6 Effect of PTX-f-CNT in comparison with PTX alone and PTX-CNT 
on SVGp12 and U87-MG 
Utilization of f-CNTs, including SWNTs and MWNTs were achieved with two different 
surfactants, namely PEG400 and PF127. Each f-CNTs was conjugated with four 
different concentrations of PTX. As controls, individually PTX, PF127 and PEG400 
were compared with f-CNTs-PTX complexes. Data were expressed using Two-way 
ANOVA, followed by Bonferroni‟s multiple comparison test to demonstrate the 
significance (p<0.05) of the formulations. Furthermore, the IC50 for each formulation 
was carried out to show the concentration of PTX that was required for 50% inhibition 
on each cell line. 
5.6.1 Cytotoxic effect of CNT-PTX conjugate functionalized with PF127 and 
PEG400 on SVGp12  
Data shown in Figure 5.17 demonstrated the effect of all formulations utilized on 
human astrocytes cell line (SVGp12). Respective cell lines were treated for 24 and 48 
hours. Observed data showed significant differences (p<0.001) for all formulations once 
compared to untreated. As expected PEG400, PF127, MWNTs and SWNTs showed no 
significant difference. PTX alone had a very significant effect at both time intervals 
(p<0.0001). Although, formulations of PTX conjugated with f-CNTs demonstrated to be 
less toxic. Moreover, SWNT-PF127-PTX was confirmed to have significantly lower 
toxicity effects, maintaining cell viability of 66.10% ± 2.1 at 24 hours (p<0.005). 
Nevertheless, same formulations showed similar cell viability when treated for longer 
period (48 hours) and no significant differences was found when compared to one 
another.  
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Figure 5.17 SVGp12 cell lines treated with different f-CNTs formulations. The error 
bars represent the standard deviation (SD) of three samples 
 
One-way ANOVA was also performed to demonstrate the difference between the 
formulations and time intervals. Significant differences were observed in between 24 
hours and 48 hour time frames, indicating that same formulation killed more cells in 48 
hours with the same concentration (p<0.05).  
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Cytotoxicity of all formulations investigated on SVGp12, is demonstrated in Figure 
5.18 and proposed to be concentration dependent. However, positive controls, MWNTs 
and SWNTs showed no significant toxicity on cells.  
 
 
Figure 5.18 Cytotoxicity effect of formulations in viability percentage of SVGp12. The 
error bars represent the standard deviation (SD) of three samples 
 
IC50 values in Table 5.3, showed that PTX alone had the lowest IC50 value (5.9 mg/ml), 
indicating that utilization of PTX used alone had more substantial toxic effect on 
astrocytes in comparison to PTX-f-CNT, followed by MWNT-PEG-PTX and MWNT-
PF127-PEG with respective values of 5.99 ± 1.9 and 5.99 ± 1.7.  
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Lowest IC50 value for f-CNTs was SWNT-PEG-PTX (6.85 ± 2.4) demonstrating the 
lowest cytotoxic effect on human cell lines. However, no significant differences could 
be ascertained for any of the formulations when directly compared to one another.  
 
Table 5.3 IC50 Values of the formulations in mg for SVGp12 cells 
 
 
Formulations  
IC50 mg ± SD 
SVGp12  
PTX  5.92 ± 1.1 
SWNT-PTX 6.4  ± 1.0 
SWNT-PEG-PTX   6.75 ± 1.8 
SWNT-PF127-PTX 6.85 ± 2.4 
MWNT-PTX 7.3  ±  0.8 
MWNT-PEG-PTX 5.99 ± 1.9 
MWNT-PF127-PTX 5.99 ± 1.7 
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5.6.2 Cytotoxic effect of PF127 and PEG400 functionalized SWNT/MWNT and 
PTX conjugates on U87-MG 
Comparison for all formulations were carried out and only formulations of f-CNTs 
showed a significant difference on U87-MG cells (p<0.05). While, PTX treated cells 
showed cell viability of 60% ± 2.1 (Figure 5.19). 
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Figure 5.19 U87-MG cell lines treated with f-CNTs for 24 and 48 hours. The error bars 
represent the standard deviation (SD) of three samples 
 
MWNT-PEG-PTX and MWNT-PF127-PTX complexes showed a significantly lower 
cell viability of 38% ± 1.9 and 40% ± 1.3, respectively (p<0.001). Subsequently, from 
all f-CNTs, a significant difference between cell viabilities was detected between 
SWNT-PEG-PTX and MWNT-PF127-PTX with values of 44% ± 2.6 and 38% ± 1.3, 
respectively (Figure 5.20). However, significant differences were observed between 24 
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hours and 48 hours, indicating that same formulation killed more cells in 48 hours with 
the same concentration (p<0.05). 
 
Figure 5.20 Microscopic picture of U87-MG cell lines treated with various CNTs 
formulations (x200) 
 
Cytotoxicity of all formulations on U87-MG is illustrated in Figure 5.21 and elicited 
concentration dependency. Controls, MWNTs and SWNTs as well as PEG and PF127 
examined on U87-MG, showed no significant toxicity. 
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Figure 5.21 Cytotoxicity effect of formulations in viability percentage of SVGp12  
The error bars represent the standard deviation (SD) of three samples 
 
IC50 values of all formulations are shown in Table 5.4. It appeared that a higher dose of 
PTX (11 mg) alone was required to kill 50% of cells, a significant difference is 
noticeable in comparison to SWNT-PEG-PTX (4.3 mg) that demonstrated the lowest 
IC50 values (p<0.01).  
Table 5.4 IC50 Values of the formulations in mg for U87-MG cells 
Formulations  
IC50 mg ± SD 
U87-MG  
PTX  11.0 ± 2.0 
SWNT-PTX 7.70 ± 1.5 
SWNT-PEG-PTX   4.3 ± 1.7 
SWNT-PF127-PTX 3.5 ± 1.4 
MWNT-PTX 7.6 ± 1.6 
MWNT-PEG-PTX 4.5 ± 0.9 
MWNT-PF127-PTX 3.9 ± 1.3 
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5.7 Conclusions 
Cytotoxicity of CNTs and f-CNTs-PTX were investigated on SVGp12 and U87-MG.    
Growth curves concluded that the U87-MG cells grow faster compared to SVGp12 
cells. No significant difference was found with treatment of PTX-CNTs on both cells 
line at both time intervals. It was only significantly evident that cell viability was 
decreased when PTX concentration was increased (p<0.05). p-CNTs showed not to be 
toxic to normal astrocyte cell lines even at high concentrations of 15 mg/ml. 
CNTs-PTX complexes demonstrated no effect on both cell lines at 24 and 48 hours. 
Once formulations were assessed for cytotoxic effects on U87-MG, f-CNTs were shown 
to decrease cell viability significantly in comparison to PTX alone. Moreover, f-CNTs 
may provide better targeting, reduced toxicity and enhanced decrease in glioma cell 
viability. Promisingly, lower PTX concentrations were required to kill equivalent 
numbers of cells with respect to PTX alone. Thus the utilization of carbon nanotubes 
has demonstrated a dynamic approach to address toxicity issues with anti- cancer 
agents.
  
159 
 
 
CHAPTER 6 
CONCLUSIONS  
& 
FUTURE STUDIES 
 
„‟ Finally, in conclusion, let me say just this‟‟ 
(Peter Sellers)
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CHAPTER 6 
6.1 Conclusions and future work 
CNTs have been functionalized and characterized using a wide variety of techniques. 
They have been shown to be of appropriate size, biocompatible and ideal for drug 
delivery applications. A paramount factor is their aqueous solubility and stability which 
has been demonstrated for a period of 10 days, showing no significant difference in the 
ζ-potential. Freeze drying formulations could lead to a higher stability for longer period 
of time. The stability over extended periods of time holds tantalising possibilities for 
future work.  
 
Loading efficiency of PTX confirmed that f-CNTs have an enhanced ability to load 
more drug molecules owing to the branched functional groups acting as anchors for the 
drug. Interestingly, their efficiency was highly dependent on drug concentration; 
however when 200 µg/ml of PTX was reached, loading efficiency dropped suddenly 
suggesting a stoichiometric effect due to non-covalent functionalization of the surfactant 
onto CNT walls. Nevertheless, this hypothesis would require verification through 
further experimental studies with different types CNTs, varying in diameters and 
lengths.  
 
 f-CNTs have demonstrated no significant toxic effect on SVGp12. In contrast, both f-
SWNT and f-MWNT showed significantly lower cell viability than the individual drug 
alone on the glioblastoma cell lines. Moreover, a more pronounced decrease in cell 
viability was achieved at lower concentrations of PTX, showing an overall 
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improvement in lowering the cytotoxicity on normal astrocyte cell lines. It must be 
noted however that the shape and size of CNTs are critical factors, affecting the toxicity 
and efficiency of drug delivery systems. They moreover affect the cytotoxicity of CNTs 
which was assessed through MTT assay defining cell viability. MTT assay reagent 
binds to the CNTs thus creating uncertainty in the cytotoxicity assessment.  
 
SWNTs and MWNTs have demonstrated biocompatibility, suggesting that if cultured 
for longer period of time, negative effects are likely due to physical rather than chemical 
interactions. More work is required to establish biological consequences associated with 
long-term interactions of SWNTs and MWNTs with brain cells. The findings of this 
research are encouraging to say the least however further research into the utilization of 
SWNTs and MWNTs for in vivo applications in cell systems is a necessity. Enormous 
interest to explore these formulations on animal models whereby the serum chemistry 
can be identified may be the way forward to progress this area of research.  
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